Fundraising Fox
New York · Seed–Late Stage · 93 people tracked
Also known as ORBIMED ADVISORS LLC
Find your way into OrbiMed
Sign up to see every warm intro you have to OrbiMed
- Paths you didn't know you had: your email and LinkedIn already hold routes to the OrbiMed team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
OrbiMed invests globally across the entire healthcare industry, from early-stage private companies to large multinational corporations. Its focus spans biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services, targeting innovations that improve patient outcomes and address unmet medical needs. With over 25 years of investing experience, the firm deploys capital across both public and private markets worldwide, backed by a team of scientific, medical, and investment professionals. The firm aims to support companies driving healthcare innovation and helping humanity live healthier, longer, and more productive lives.
Source: firm website, verified Oct 13, 2026.
Team · 93 people
from the firm's website & curated & public directories
Arun Sadhanandham is a Managing Director in private equity at OrbiMed, where he works as an investment professional focused on the Asia market. He holds a degree from IIM Bangalore.
David Bonita is a physician-investor (MD, Harvard; clinical work at Mass General) with over two decades investing, rising to General Partner in 2020, and board roles in oncology and therapeutics.
David Wang is a Partner and Senior Managing Director on OrbiMed's Asia team, focused on Greater China, which he joined in 2011. He previously led healthcare investments in China as a Managing Director at WI Harper Group and served as Head of Business Development at Siemens Medical Solutions, overseeing molecular diagnostics and diagnostic imaging strategy. He co-founded personalized medicine company First Genetic Trust as EVP, chaired The SNP Consortium Management Committee while at Bristol-Myers Squibb, and holds an M.D. from Peking University Medical School and a doctorate in Developmental Biology from Caltech.
Dina Chaya is a Partner on OrbiMed's Private Equity team, which she joined in 2023, and has worked in healthcare private equity and venture capital since 2001. Before OrbiMed, she held roles at Omega Funds, NeoMed, 3i, and Index Ventures. She holds a B.A. in Natural Sciences from the University of Cambridge and a Ph.D. in Molecular and Cellular Biology from Paris VI University, and is a CFA charterholder.
Diyong Xu is a Partner at OrbiMed with a career progression spanning analyst, associate, vice president, and principal roles at the firm. His investment experience covers biotechnology, biopharmaceuticals, medical devices, and diagnostics across venture capital, private equity, and investment banking contexts.
Evan Caplan is a Partner at OrbiMed, which he joined in 2018, where he focuses on venture investments in therapeutics, medical devices, and healthcare technology and services. Before OrbiMed, he worked as an investment banker at J.P. Morgan, advising public and private biotech, medtech, and healthtech companies. He holds a B.A. from Middlebury College and both an M.D. and an M.B.A. from Harvard.
Geoffrey C. Hsu combines Harvard Medical School training and healthcare investment-banking experience with long-tenured public-equity portfolio management since 2005 and a London-listed biotech trust role, giving him cross-border market insight.
Matthew Rizzo heads a royalty and credit team, directed over $6 billion in structured credit and royalty deals, and brings 30 years of healthcare experience including pharma licensing and acquisitions.
Mona Ashiya is a General Partner at OrbiMed, which she joined in 2010. She previously worked on J.P. Morgan's biotechnology equity research team and held positions at the Global Alliance for TB Drug Development and Harvard Business School. She holds a B.A. from the University of California, Berkeley, a Ph.D. in Cellular, Molecular, and Developmental Biology from the University of Pittsburgh, and completed a post-doctoral fellowship at the Dana Farber Cancer Institute.
Peter Thompson is a General Partner at OrbiMed, which he joined in 2010, with over 25 years of industry experience. He previously held executive roles at Becton-Dickinson and Chiron, co-founded and served as CEO of Trubion Pharmaceuticals, co-founded several OrbiMed portfolio companies, and worked at the National Cancer Institute after internal medicine training at Yale. He holds a bachelor's degree in Molecular Biology and Mathematics and a medical degree from Brown University, and is a board-certified internist and oncologist.
Partner at OrbiMed holding an M.D.
Sven H. Borho, a founding partner, leads public equities and portfolio management for listed healthcare strategies, uniquely combining specialist biomedical expertise with a science-first approach prioritizing biology and clinical science.
Partner at OrbiMed holding both M.D. and Ph.D. degrees.
Trevor Polischuk joined OrbiMed in 2003 as the Global Pharmaceutical Analyst covering Japan, and became a Partner in 2011, later serving as co-Portfolio Manager of the Worldwide Healthcare Trust. He previously worked as a Senior Research Analyst covering the U.S. pharmaceutical industry at Lehman Brothers and began his career on the Pharmaceutical Global Marketing Planning team at Warner-Lambert. He holds a B.S. in Biology and a Ph.D. in Neuropharmacology and Gross Human Anatomy from Queen's University, as well as an M.B.A. from Queen's M.B.A. for Science & Technology program.
Carter Neild spearheads expansion into healthcare royalties and Asia-focused private investments, combining a hybrid background in alternatives and bank-affiliated asset management (UBS, First Chicago) with deep University of Chicago ties.
Clay DeMarcus is a Principal in Private Equity / Venture Capital at OrbiMed. He previously worked at Bank of America as a Vice President in Equity Research covering medical technology and as an Investment Banking Associate in the healthcare group, and earlier held a role in operations at Accenture Strategy. He holds an undergraduate degree from Vanderbilt University and an MBA from Emory University's Goizueta Business School.
Ran Geng is a Principal at OrbiMed, where the focus is on investing in biotech companies and healthcare technologies. Areas of investment include treatments for diseases, technologies addressing disparities in healthcare resources, and improvements to healthcare delivery efficiency.
Kip Kitur is a Principal on the Private Equity team at OrbiMed, focusing on healthcare investments. Previously, he worked as a Consultant in The Boston Consulting Group's Healthcare practice in New York and co-founded Sarora Dairies LLC/Ltd, which processes and distributes dairy products in Kenya. He holds a Ph.D. in Pharmacology from Columbia University and a B.A. in Chemistry from Harvard College.
Sivathanu is a Principal at OrbiMed Advisors, where he invests in biotech, medtech, and diagnostics companies across their development lifecycle. He previously worked as a biotechnology equity research analyst at Evercore ISI and as a management consultant at Simon-Kucher, focusing on drug pricing and commercial strategy in the biopharma and medtech sectors. He holds a Ph.D. in Biomedical Engineering and Technology Commercialization from MIT, with research focused on muscle strength enhancement and personalized medicine approaches in cancer therapy.
Iain Dukes is a Venture Partner at Orbimed and CEO of Viriom Inc, serving on the executive teams or boards of nine companies across the USA, France, and the UK. His career includes roles as Senior Vice President of Business Development & Licensing at Merck, where he managed licensing deals for Merck Research Laboratories, as well as Vice President of External Research and Development at Amgen, President and CEO of Essentialis Therapeutics, and Vice President of Scientific and Technology Licensing at GlaxoSmithKline. He holds a BSc in Pharmacology from the University of Bath, an MSc in Cardiovascular Studies from the University of Leeds, a DPhil in Physiology and Pharmacology from the University of Oxford, and an MA in Jurisprudence and Law from the University of Oxford.
Klaus Veitinger joined OrbiMed in 2007 as a Venture Partner, focusing on venture investments in therapeutics, and has held board roles at various OrbiMed portfolio companies. He previously served as CEO of Schwarz Pharma Inc., overseeing its U.S. and Asia businesses through the sale of the Schwarz Group, and spent seven years as a Director of PhRMA. He holds a medical degree and Ph.D. from the University of Heidelberg and an M.B.A. from INSEAD.
Sevgi Gurkan joined OrbiMed in 2018 as a Venture Partner. She was previously a founding member of Merck Research Laboratories' South San Francisco Discovery site and a Director in Early Drug Development at MRL. Earlier in her career she was an Associate Professor at Rutgers, Director of the Pediatric Kidney Transplant Program at RWJ University Hospital, and a pediatric nephrologist; she holds a medical degree from Hacettepe University and a Master of Science in Clinical Research from Mount Sinai School of Medicine.
Andrew P. Kanarek serves as Chief Risk Officer at OrbiMed Advisors LLC. He works in the investment management industry, with experience spanning equity research, hedge funds, venture capital, asset management, and investment banking. He holds the CFA and CIPM designations.
Bob Smith joined OrbiMed in 2024 as a Venture Partner, bringing over thirty years of experience across alliance management, business development, commercial, M&A, and R&D roles. He retired from Pfizer in January 2024, where he led the company's global gene therapy business, its R&D business development activities, and strategic transactions team; he originally joined Pfizer in 2009 through its acquisition of Wyeth, where he led the global M&A group. He holds a B.S. in Neuroscience and an M.B.A. in Finance and Corporate Accounting from the University of Rochester.
Scot Stevens is a General Partner and Co-Head of Public Equity at OrbiMed, which he joined in 2005, where he leads trading activities across the firm's business units, geographies, and investment products. Before OrbiMed, he worked in Global Banking & Markets at Goldman, Sachs & Co., trading equity products for healthcare-focused hedge fund clients. He holds an M.B.A. from The Wharton School at the University of Pennsylvania and a B.S. in Business Administration with a minor in Chemistry from the University of North Carolina at Chapel Hill.
Carl Gordon, an MIT Ph.D. and CFA with early hands‑on ImClone experience, is a founding GP and Co‑Head of global private equity repeatedly named to Forbes' Midas List and media‑shy.
Elizabeth Krane is an Analyst at OrbiMed, where she focuses on healthcare investing. She graduated from Southern Methodist University in 2016 with a BA in Economics and a BBA in Finance with a specialization in Alternative Asset Management. During her time at SMU, she served as captain of the varsity swimming team.
Jim Sullivan joined OrbiMed as a Venture Partner in 2019 and serves as CEO of portfolio company Vanqua Bio, which develops therapeutics for neurological conditions such as Parkinson's disease. He previously was Vice President of Research at AbbVie, overseeing research across oncology, immunology, neurology, hepatitis C, and cystic fibrosis, and has advanced more than 100 compounds into clinical development. He holds a bachelor's degree and Ph.D. in biochemistry from Trinity College Dublin, completed postdoctoral research in neurobiology at Northwestern University, and is an adjunct faculty member there.
Joshua Golomb is a partner at OrbiMed Advisors, where he focuses on investments in therapeutics. His expertise spans global pharmaceuticals, specialty pharmaceuticals, and biotech.
Sumona Chakraborty is an Executive Director on OrbiMed's Asia private equity team, which she joined in 2018. Before OrbiMed, she worked in investment banking at Avendus Capital, and earlier at Equirus Capital and UBS. She holds a Bachelor of Technology in Biotechnology from the National Institute of Technology, Warangal and an M.B.A. from S.P. Jain Institute of Management and Research, Mumbai.
Founder mafia
14 people who came through OrbiMed went on to found or lead other companies.
+ 2 more
What they invest in
from 278 of 337 portfolio companiesBiotech ×212Healthtech ×179Medical Devices ×92Digital Health ×49AI & Machine Learning ×38Deep Tech ×28Hardware ×17Advanced Manufacturing ×10
HQs:United States×183China×11India×11Switzerland×3United Kingdom×3Denmark×2
Who they back
founder profiles across 102 portfolio companiesFounding team size:solo founder×412 founders×323 founders×154+ founders×14
Where their founders studiedfrom 79 founders with education data
Massachusetts Institute of Technology ×5Stanford University ×4Harvard Medical School ×3MIT Sloan School of Management ×3Princeton University ×3Stanford University School of Medicine ×3University of California, Berkeley ×3Ben-Gurion University of the Negev ×2
What their founders studiedfrom 82 founders with field-of-study data
Life Sciences ×28Medicine ×21Engineering ×15Chemistry ×13Business & Management ×12Computer Science ×8Finance & Accounting ×4Physics ×3
Where their founders worked beforefrom 85 founders with career history
Stanford University ×4Atlas Venture ×3Dana-Farber Cancer Institute ×3Harvard Medical School ×3Aisling Capital ×2ARCH Venture Partners ×2GlaxoSmithKline ×2M.D.G Medical Ltd. ×2
Accelerator rootsportfolio companies that came through a program
46 founders hold a PhD · 12 hold an MBA (of 88 with degree data) · backed the same founder in 2+ companies: 4 founders
Investments · 337 tracked
founders shown can be your intro pathBy year:2026 · 102025 · 252024 · 122023 · 92022 · 82021 · 212020 · 112019 · 162018 · 92017 · 72016 · 92015 · 12161 dated
Q32 Bio is a biotechnology company developing therapies for autoimmune and inflammatory diseases, with a scientific focus on the complement system and immune regulation in conditions such as inflammation, autoimmunity and fibrosis.
BiotechHealthtech
Shelia Violette(Founder & Chief Scientific Officer)inMichael Holers(Co-founder)Jodie Morrison(Chief Executive Officer)inLee Kalowski(President & Chief Financial Officer)Maria Marzilli(Chief Business Officer)inDavid Appugliese(Senior Vice President, Head of People)in
Co-investorsAtlas VentureAgent CapitalCU Healthcare Innovation FundOUP (Osage University Partners)Sanofi Ventures5AM Ventures+2 more
Scribe is a molecular engineering company developing CRISPR-based genetic therapies to treat cardiometabolic disease and other conditions.
BiotechDeep TechHealthtechMedical DevicesBerkeley, US
Benjamin Oakes(Founder)inJennifer A. Doudna, PhD(Co-founder, Scientific Advisor)Benjamin L. Oakes, PhD(Co-founder, President and CEO)David F. Savage, PhD(Co-founder, Scientific Advisor)Brett Staahl, PhD(Co-founder, VP of External Innovation)Brett Staahl(Founder)
Co-investorsAndreessen HorowitzAvoro Capital AdvisorsMenlo VenturesRA CapitalWellington Management
Sionna Therapeutics is a biopharmaceutical company founded in 2019 that develops small-molecule therapies for cystic fibrosis by targeting and stabilizing NBD1, the domain of the CFTR protein where the common ΔF508 mutation occurs.
BiotechHealthtechMedical Devices
Greg(Co-founder & Senior Vice President of Discovery Research)Mark(Co-founder & Senior Vice President of Medicinal Chemistry)Mike(President & CEO)Charlotte(Chief Medical Officer)Elena(Chief Financial Officer)Caroline(Chief Business Officer)
Co-investorsAtlas VentureRA CapitalViking Global
Upstream Bio is a biotechnology company that sponsors clinical trials to develop products under investigation.
BiotechHealthtechWaltham, US
Rand Sutherland(Chief Executive Officer)inAllison Ambrose(General Counsel)inAaron Deykin(Chief Medical Officer & Head of R&D)inMike Gray(Chief Financial Officer and Chief Operating Officer)Adam Houghton(Chief Business Officer)inStacy Price(Chief Technology Officer)in
Co-investorsAccess IndustriesAccess BiotechnologyBain Capital Life SciencesDecheng CapitalHBM Healthcare InvestmentsHBM Partners+5 more
Aadi Bioscience develops therapies targeting mTOR-driven diseases using precision medicine and albumin-bound nanoparticle technology, applying genomic profiling to identify patients most likely to benefit from mTOR inhibition.
BiotechHealthtechMorristown, US
Scott Giacobello(Executive Officer)inBryan Ball(Executive Officer)Dave Lennon(Executive Officer, Director)inDavid Dornan(Executive Officer)James Murphy(Executive Officer)Stephen Pakola(Executive Officer)
Board seatChau Khuong· per SEC Form D · $41.8M raise · filed Mar 2017
Co-investors3B Future Health FundAlly Bridge GroupDecheng CapitalVivo Capital
Adicet Bio develops allogeneic gamma delta CAR T cell therapies for patients with autoimmune diseases and cancer.
BiotechHealthtechMenlo Park, US
Aya Jakobovits(Executive Officer, Director)Nathan Hubbard(Executive Officer)inChen Schor(President, Chief Executive Officer and Director)in
BoardFlorent Gros(Director)
Board seatJonathan SilversteinCarl Gordon· per SEC Form D
Co-investorsForesite CapitalPontifax Venture CapitalQuan CapitalaMoonNovartis Venture FundPureTech Health
Arvinas is a biopharmaceutical company developing PROTAC protein degrader therapies, with a pipeline focused on oncology and neurology.
BiotechHealthtechNew Haven, US
Sean Cassidy(Executive Officer)inManuel Litchman(Executive Officer, Director)inRandy Teel(President and Chief Executive Officer; Director)inCraig Crews(Founder)
BoardLiam Ratcliffe(Director)in
Board seatStephen Squinto· per SEC Form D · $55M raise · filed Apr 2018
Co-investors5AM VenturesAccess BiotechnologyCanaan PartnersConnecticut InnovationsElm Street VenturesNextech Invest+3 more
CalciMedica is a clinical-stage biopharmaceutical company developing CRAC (calcium release-activated calcium) channel inhibition therapies for serious acute and chronic inflammatory, immunologic, and cardiopulmonary diseases.
BiotechHealthtechLa Jolla, US
Kenneth A. Stauderman(Co-founder)inGonul Velicelebi(Co-founder)Daniel Geffken(Executive Officer)A. Rachel Leheny(Executive Officer, Director)Michael J. Dunn(Executive Officer)inStephen Bardin(Chief Financial Officer)in
Board seatChau Khuong· per SEC Form D
Co-investorsAisling CapitalMESA VERDE VENTURE PARTNERSRevelation PartnersSanderling VenturesClarus Ventures
Compass Therapeutics uses proprietary antibody discovery platforms to generate and screen diverse panels of monoclonal and multispecific antibodies, aiming to identify synergistic therapeutic combinations.
BiotechHealthtechCambridge, US
Schuetz Thomas(Executive Officer, Director)inErrik Anderson(Executive Officer, Director)inThomas J. Schuetz(Executive Officer, Director)inVered Bisker-Leib(Executive Officer)inBarry Shin(Chief Financial Officer)inNeil Lerner(Senior Vice President, Chief Accounting Officer)in
Board seatStephen SquintoCarl Gordon· per SEC Form D
Co-investorsAlumni VenturesBioBritF-Prime CapitalForesite CapitalGV (Google Ventures)venBio Partners+3 more
Imara is a clinical-stage biopharmaceutical company developing small molecule therapeutics for unmet medical needs, currently advancing ELVN-001, a selective kinase inhibitor designed to treat chronic myeloid leukemia by targeting the BCR-ABL gene fusion.
BiotechCambridge, US
James G. McArthur(Executive Officer, Director)Christoph M. Adams(Executive Officer, Director)Richard Fair(President, Chief Executive Officer, Director)
BoardSara Nayeem(Director)Barbara Dalton(Director)David Mott(Director)
Board seatDavid Bonita· per SEC Form D
Co-investorsBay City CapitalNew Enterprise Associates (NEA)Pfizer Venture InvestmentsRA CapitalAlexandriaArix Bioscience+3 more
Keros is a clinical-stage biopharmaceutical company developing product candidates that modulate signaling of the transforming growth factor-beta (TGF-β) family of proteins to treat disorders affecting blood cells and tissues such as bone, muscle, adipose and heart.
BiotechHealthtechLexington, US
Jasbir Seehra(Co-Founder, Chief Executive Officer and Director)in
BoardJulius Knowles(Director)Alon Lazarus(Director)inOhad Hammer(Director)Ran Nussbaum(Director)in
Board seatCarl Gordon· per SEC Form D
Co-investorsArkin CapitalForesite CapitalPontifax Venture Capital
A Spanish-language blog that publishes articles on health and medicine topics, such as flu prevention and vaccination recommendations, for general readers.
BiotechMedia & EntertainmentAustin, US
Matthew Winkler(Director)Sinil Kim(Executive Officer)inPaul Lammers(Executive Officer, Director)inJon Irvin(Executive Officer)Casi DeYoung(Executive Officer)
BoardMichael Powell(Director)
Board seatChau Khuong· per SEC Form D · $80M raise · filed Jun 2019
Co-investorsNew Enterprise Associates (NEA)Pfizer Venture InvestmentsCorrelation VenturesOUP (Osage University Partners)Pfizer VenturesSofinnova Ventures
Nextcure is a clinical-stage biopharmaceutical company developing immunotherapies targeting IO pathways, with a focus on oncology applications.
BiotechBeltsville, US
Michael Richman(Executive Officer, Director)Timothy Mayer(Executive Officer)inUdayan Guha(Executive Officer)inSteven P. Cobourn(Executive Officer)inSourav Kundu(Executive Officer)inKevin Shaw(Executive Officer)in
Board seatChau Khuong· per SEC Form D
Co-investorsBay City CapitalCanaan PartnersLAVLilly Asia VenturesPfizer Venture InvestmentsQuan Capital+4 more
Prelude Therapeutics is a precision oncology company developing cancer treatments for areas of high unmet need, with a pipeline including selective KAT6A degraders and mutant-selective JAK2V617F JH2 inhibitors.
BiotechHealthtechNewark, US
Krishna Vaddi(Executive Officer, Director)
BoardPaul Friedman(Director of Issuer)
Board seatDavid Bonita· per SEC Form D
Co-investorsThe Innovation Space
SI-BONE develops medical devices for treating sacroiliac (SI) joint dysfunction and chronic low back pain, targeting patients and physicians.
HealthtechMedical DevicesSan Jose, US
Mark Reiley(Director)inJeffrey W. Dunn(Executive Officer, Director)Robert E. Johnson(Executive Officer)Dan Murray(Executive Officer)Laura A. Francis(Chief Executive Officer)
BoardTimothy E. Davis(Director)
Board seatDavid Bonita· per SEC Form D · $21M raise · filed Jun 2016
Co-investorsArboretum VenturesMontreux Equity Partners
Spruce Biosciences develops and commercializes therapies for serious neurological and endocrine disorders with unmet medical need, with a lead investigational enzyme replacement therapy (TA-ERT) for Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome Type B).
BiotechHealthtechSouth San Francisco, US
Samir Gharib(Executive Officer)inRICHARD KING(Executive Officer, Director)inJavier Szwarcberg(Chief Executive Officer)in
BoardSimpson Camilla(Director)Tiba Aynechi(Director)inBali Muralidhar(Director)in
Board seatDina Chaya· per SEC Form D · $53.6M raise · filed Feb 2023
Co-investorsAisling CapitalHealthCapRiverVest Venture PartnersAbingworthNorwest Venture PartnersNovo Holdings+1 more
Synlogic develops synthetic biology-based biotherapeutics that use engineered living organisms to treat diseases.
BiotechDeep TechMedical DevicesCambridge, US
Bharatt Chowrira(Executive Officer)inMichael Sheahan(Executive Officer)Jose Carlos Gutierrez-Ramos(Executive Officer, Director)inPaul Miller(Executive Officer)inAoife Brennan(Executive Officer)inTodd Shegog(Executive Officer)in
Board seatChau Khuong· per SEC Form D · $42M raise · filed May 2017
Co-investorsAtlas VentureCLI VenturesNew Enterprise Associates (NEA)NSG VenturesPfizer Venture InvestmentsSofinnova Ventures+1 more
Adaptive Biotechnologies applies the genetics of the adaptive immune system to diagnostics and therapeutics, translating immune-system data into clinical insights for clinicians and biopharma companies.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesSeattle, US
Chad Robins(Chief Executive Officer, Co-founder, Chairman of the Board)inHarlan Robins(Co-founder; Chief Scientific Officer until 2026)inKathleen Determann(Executive Officer)inDean Schorno(Executive Officer)inChris Carlson(Executive Officer)Kyle Piskel(Chief Financial Officer)in
Co-investorsDecheng CapitalFMG CapitalForesite CapitalKhosla VenturesViking GlobalCasdin Capital
Alumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases.
AI & Machine LearningBiotechDigital HealthHealthtechLongevitySouth San Francisco, US
Martin Babler(President, Chief Executive Officer and Chairman of the Board)inMark Bradley(Chief Development Officer)inKolbot By(SVP, Head of Technical Operations)inJack Danilkowicz(Chief Commercial Officer)inJörn Drappa(Chief Medical Officer)inDavid M Goldstein(Chief Scientific Officer)in
Co-investorsForesite CapitalGeneral AtlanticHBM Healthcare InvestmentsHBM PartnersNextech InvestSamsara BioCapital+4 more
Aura Biosciences develops Virus-Like Drug Conjugates (VDCs), a platform using Virus-Like Particles conjugated with drugs or loaded with nucleic acids to target solid tumors.
BiotechHealthtechMedical DevicesCambridge, US
Elisabet de los Pinos, Ph.D.(Executive Officer, Director)Elisabet de los Pinos(Founder)inMichael Wyzga(Executive Officer)Dale Pfost, Ph.D.(Director)Alan E. Walts, Ph.D.(Director)Lewis Geffen(Executive Officer)
Co-investorsAdvent Life SciencesChiesi VenturesColumbus Venture PartnersDroia VenturesForesite CapitalJazzya Investments+6 more
RECELL is an FDA-approved autologous skin cell suspension device for treating burns, trauma, and surgical wounds by harvesting a patient's own skin cells and applying them to accelerate healing and reduce the need for large skin grafts.
BiotechHealthtechMedical DevicesMelbourne, US
Fiona WoodDale A Sander(Executive Officer)inCary Vance(Executive Chairman & Interim Chief Executive Officer)in
BIOAGE develops therapies targeting the molecular pathways that drive aging to increase healthspan and address age-related chronic diseases.
BiotechHealthtechLongevityRichmond, US
Kristen Fortney, PhD(Co-Founder, CEO)Eric Morgen, MD(Co-Founder, COO)Kristen Fortney(Founder)inEric Morgen(Founder)inDov Goldstein(Executive Officer)in
BoardPatrick Enright(Director)in
Co-investorsAndreessen HorowitzElad GilFelicis VenturesGreen Sands EquityIA Seed VenturesLongitude Capital+19 more
BiomX builds a portfolio of defense and security companies through subsidiaries, partnerships, and acquisitions, focusing on detection systems, aerial technologies, and infrastructure security.
AI & Machine LearningBiotechCybersecurityDeep TechDefense TechHardwareNess Ziona
Jonathan Solomon(Chief Executive Officer)inMerav Bassan(Chief Development Officer)inMarina Wolfson(Chief Financial Officer)inJesse Goodman(Director)Alan Moses(Director)Jonathan Leff(Director)
Co-investorsAMR Action FundBaruch Future VenturesNSG VenturesSBI JI Innovation Advisory Ltd.Seventure Partners8VC+2 more
Caris Life Sciences is a precision medicine company focused on molecular profiling and research to support cancer care and improve patient outcomes.
AI & Machine LearningBiotechDigital HealthHealthtechMedical Devices
David Dean Halbert(Chairman, Founder and CEO)
Co-investorsCoatue ManagementSilver Lake PartnersSixth StreetBraidwellMillennium Management
Crinetics is a pharmaceutical company focused on discovering, developing, and commercializing therapies for endocrine diseases and endocrine-related conditions.
BiotechSan Diego, US
Richard Scott Struthers(Executive Officer, Director)Stephen Betz(Chief Scientific Officer)inR. Scott Struthers(President, Chief Executive Officer and Director)inTobin Schilke(Chief Financial Officer)inIsabel Kalofonos(Chief Commercial Officer)inYunFei Zhu(Executive Officer)
Co-investors5AM VenturesForesite CapitalRA CapitalVivo Capital
Cullinan Therapeutics is a clinical-stage biotech company developing therapeutic molecules for autoimmune diseases and cancer, with expertise in immune modulation.
BiotechHealthtechMedical Devices
Mary Kay Fenton(Chief Financial Officer)inJeffrey Jones(Chief Medical Officer)Jennifer Michaelson(Chief Scientific Officer)inCorinne Savill(Chief Business Officer)inJacquelyn Sumer(Chief Legal and Compliance Officer and Secretary)inNadim Ahmed(President and Chief Executive Officer)in
Co-investorsForesite CapitalNextech InvestBiotechnology Value Fund
CytomX is a clinical-stage biopharmaceutical company developing conditionally activated biologic cancer therapies, including antibody-based treatments designed to target tumors while limiting effects on healthy tissue.
BiotechHealthtechSouth San Francisco, US
Sean A. McCarthy(Chief Executive Officer and Chairman)inMarcia P. Belvin(SVP, Chief Scientific Officer)inDawn Benson(SVP, Quality and Product Manufacturing)inWayne Chu(Chief Medical Officer)Rachael Lester(SVP, Chief Business Officer)inChris Ogden(Chief Financial Officer)in
Co-investorsATEL VenturesCanaan PartnersLongitude CapitalPfizer Venture InvestmentsWellington ManagementThird Rock Ventures
Damora Therapeutics is a preclinical-stage biotechnology company that discovers and develops therapeutic candidates, including DMR-001, DMR-002, and DMR-003, with the goal of advancing treatments through investigational drug applications and clinical trials.
BiotechCopenhagen, US
Garrett Winslow(Executive Officer)inLori Firmani(Executive Officer)inHans T. Schambye(Executive Officer, Director)Jennifer Jarrett(President, Chief Executive Officer and Director)inBecker Hewes(Chief Medical Officer)Sherwin Sattarzadeh(Chief Operating Officer)
Co-investorsAccess BiotechnologyViking GlobalAndreessen HorowitzBAM ElevateBay City CapitalCommodore Capital+8 more
Dario provides digital tools and support to help people manage chronic conditions such as diabetes between provider visits.
BiotechDigital HealthHealthtechMental HealthWellness & FitnessNew York, US
Oren Fuerst, PhD(Director)Erez Raphael(Chief Executive Officer)inZvi Ben David(Chief Financial Officer, Treasurer, and Secretary)inSteven Nelson(Chief Commercial Officer)inGadi Levin(Executive Officer, Director)in
BoardAdam K. Stern(Director)
Co-investorsAgate Medical Investments LPLeo Capital VenturesPitango
Disc Medicine is a biopharmaceutical company developing therapies from discovery through clinical development for patients in need.
BiotechHealthtech
John Quisel(Chief Executive Officer)inJean Franchi(Chief Financial Officer)inJonathan Yu(Chief Operating Officer)inWill Savage(Chief Medical Officer)inPamela Stephenson(Chief Commercial Officer)inSteve Caffé(Chief Regulatory Officer)in
Co-investorsAccess BiotechnologyAtlas VentureBain Capital Life SciencesForesite CapitalFrazier Life Sciences5AM Ventures+7 more
Edgewise Therapeutics discovers and develops small molecule medicines targeting muscle proteins to treat neuromuscular and cardiac diseases, including sevasemten for muscular dystrophies and EDG-7500 for cardiomyopathy, leveraging a proprietary drug discovery platform based on muscle physiology and high-throughput functional assays.
BiotechDigital HealthBoulder, US
Kevin Koch(Executive Officer, Director)inAlan Russell(Director)inBadreddin Edris(Director and Co-Founder)inKenneth Harrison(Director)
BoardPeter Thompson(Director)inJonathan Root(Director)in
Co-investorsBoulder VenturesForesite CapitalUS Venture PartnersViking GlobalWellington ManagementDeerfield Management Company+1 more
Emergent BioSolutions is a public health company that develops, manufactures, and supplies medical countermeasures for national security and preparedness, along with commercialized products addressing threats such as the opioid epidemic.
Advanced ManufacturingBiotechHealthtechGaithersburg, US
Fuad El-Hibri(Director, Executive Officer)inRobert G Kramer(Executive Officer)inKatherine Strei(Executive Officer)Adam R Havey(Executive Officer)inDaniel J Abdun-Nabi(Executive Officer, Director)inJoseph C. Papa(President, CEO and Director)
Co-investorsAdvent Life Sciences
Enliven Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops small molecule therapeutics using a precision medicine approach, with a focus on oncology and hematology.
BiotechHealthtechBoulder, US
Sam Kintz(Co-founder and Head of Pipeline)inJoe Lyssikatos(Co-founder and Research Fellow)Anish Patel(Co-founder and Chief Operating Officer)Rick Fair(Chief Executive Officer and Member of the Board of Directors)inHelen Collins(Chief Medical Officer)inBen Hohl(Chief Financial Officer and Head of Corporate Development)in
Co-investors5AM VenturesPfizer Venture InvestmentsRoche Venture FundARCH Venture PartnersBay City CapitalJanus Henderson Investors+2 more
Forte Biosciences is a clinical-stage biopharmaceutical company developing FB102, an anti-CD122 monoclonal antibody intended to treat autoimmune diseases including celiac disease, vitiligo, alopecia areata, and type 1 diabetes by modulating immune cell activity.
BiotechSherman Oaks, US
Paul A. Wagner(Chairman, President, Chief Executive Officer and Director)inAntony A. Riley(Chief Financial Officer)inTuan Huynh(Director)Lawrence Eichenfield(Director)
Insmed is a biopharmaceutical company that provides grants and charitable funding to support healthcare provider education and patient care initiatives focused on nontuberculous mycobacterial lung disease, non-cystic fibrosis bronchiectasis, and other serious lung diseases.
BiotechDigital HealthHealthtechMedical Devices
Will Lewis(Chair and Chief Executive Officer)inGeoffrey AllaninSara Bonstein(Chief Financial Officer)inRoger Adsett(Chief Operating Officer)Martina Flammer(Chief Medical Officer)inS. Nicole Schaeffer(Chief People Strategy Officer)in
Co-investorsBessemer Venture PartnersF-Prime CapitalForesite CapitalHercules Capital, Inc.Prospect Venture PartnersRidgeback Capital+1 more
InspireMD develops and commercializes medical devices for vascular intervention, including carotid stent systems and embolic protection systems sold through direct sales in the United States and via distributors in international markets.
BiotechHealthtechMiami, US
Patrick Verta(Executive Officer)inPete Ligotti(Executive Officer)inMike Lawless(Chief Financial Officer)Shane Gleason(Executive Officer)inMarvin Slosman(President and Chief Executive Officer)inAndrea Tommasoli(Chief Operating Officer)
Intellia Therapeutics develops in vivo and ex vivo CRISPR/Cas9 gene editing therapies aimed at treating the root causes of severe genetic diseases, with lead candidates for hereditary angioedema and ATTR amyloidosis.
BiotechDeep TechHealthtechCambridge, US
Nessan Bermingham(Founder)inJennifer Doudna(Founder)Jose Rivera(Executive Officer)inJohn Leonard(President and Chief Executive Officer)inJames Basta(Executive Vice President, General Counsel and Corporate Secretary)inEdward Dulac(Executive Vice President, Chief Financial Officer)in
Co-investorsage1Atlas VentureAvoro Capital AdvisorsEcoR1 CapitalForesite CapitalRidgeback Capital+1 more
Invivyd is a biopharmaceutical company that develops antibody-based product candidates for the prevention and treatment of serious viral infectious diseases, combining viral surveillance and predictive modeling with antibody engineering.
BiotechHealthtechWaltham, US
Tillman U. Gerngross(Executive Officer, Director)Marc Elia(Founder)inLynn Connolly(Executive Officer)Eric Kimble(Executive Officer)inHalley Gilbert(Executive Officer)Rebecca Dabora(Executive Officer)in
Co-investorsBain Capital Life SciencesForesite CapitalGV (Google Ventures)MRL Ventures FundPremji InvestRA Capital+6 more
NeuroPace is a commercial-stage medical device company that develops the RNS System, a brain-responsive neurostimulation platform delivering real-time treatment at the seizure source for patients with drug-resistant epilepsy and other brain disorders.
Digital HealthHardwareHealthtechMedical DevicesMountain View, US
Rebecca Kuhn(Executive Officer)inFrank Fischer(Executive Officer, Director)Joel Becker(President, Chief Executive Officer and Director)inVince Burgess(Director)inRenee Ryan(Director)inRay Larkin(Director)
Co-investorsAccelmed PartnersNew Enterprise Associates (NEA)
The Oncology Institute operates a national network of 65 affiliated physician clinics and contracts with independently-owned oncology and hematology practices to deliver outpatient cancer care through fee-for-service arrangements and value-based contracts that shift financial risk to the company.
HealthtechCerritos, US
Robert Carter(Executive Officer)Jeremy Castle(Executive Officer)Daniel Virnich(Executive Officer, Director)Yale Podnos(Executive Officer)inBrad Hively(Director)Mihir Shah(Executive Officer)in
Traws Pharma (formerly Onconova Therapeutics) develops investigational antiviral agents targeting respiratory viral infections and certain cancers, with four clinical-stage programs including a cap-dependent endonuclease inhibitor for influenza and bird flu, a protease inhibitor for COVID-19, and two kinase inhibitors for solid tumors and blood cancers.
BiotechNewtown, US
Ramesh Kumar, Ph.D(Executive Officer, Director)E. Premkumar Reddy(Director)Manoj Maniar(Executive Officer)inThomas McKearn(Executive Officer)Ajay Bansal(Executive Officer)inSteven Fruchtman(Executive Officer)in
ORIC Pharmaceuticals is a clinical-stage oncology company developing therapies aimed at overcoming cancer treatment resistance, including innate, acquired, and bypass resistance.
BiotechHealthtechSouth San Francisco, US
Richard Heyman(Chairman, Founder, Scientific Advisory Board)inCharles Sawyers(Founder, Scientific Advisory Board)Scott Lowe(Founder, Scientific Advisory Board)Dominic Piscitelli(Chief Financial Officer)inPratik Multani(Chief Medical Officer)inJacob Chacko(President, Chief Executive Officer and Board Member)in
Co-investorsEcoR1 CapitalNew Enterprise Associates (NEA)Nextech InvestTaiho Ventures, LLCThe Column GroupViking Global
Passage Bio is a biotechnology company developing treatments for central nervous system (CNS) diseases, with a focus on neurodegenerative conditions.
BiotechHealthtechPhiladelphia, US
William Chou(Chief Executive Officer)Tadataka Yamada(Executive Officer, Director, Promoter)Stephen Squinto(Executive Officer, Director)in
BoardPatrick Heron(Director)inCarl Gordon(Director)inThomas Street Address 1 Woiwode(Director)
Co-investorsFrazier Life SciencesAccess BiotechnologyFrazier Healthcare PartnersLilly Asia VenturesNew Leaf Venture PartnersSphera Funds Management+2 more
Relmada is a clinical-stage biopharmaceutical company developing therapies including NDV-01, a sustained-release intravesical formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer, and Sepranolone, a candidate targeting compulsive behaviors via GABAA receptor modulation.
BiotechHealthtechNew York, US
Sergio Traversa(Executive Officer, Director)Paul Kelly(Director)Maged Shenouda(Director)inEliseo O. Salinas(President and Chief Scientific Officer)inDouglas Beck(Chief Financial Officer)Charles Ence(Chief Accounting and Compliance Officer)
Co-investorsBioAdvanceBAM ElevateBraidwellCommodore CapitalJanus Henderson InvestorsRA Capital+2 more
Shattuck Labs is a biotechnology company developing biologic medicines targeting TNF receptors, including the TL1A/DR3 axis, for patients with cancer and inflammatory or life-altering diseases.
BiotechHealthtechAustin, US
Josiah Hornblower(President/CEO)inTaylor(Co-founder & Chief Executive Officer, Board Member)
BoardWalter Loewenbaum(Director)
Co-investorsEcoR1 CapitalHatteras Venture PartnersRocky Point VenturesREDMILET. Rowe Price
Sonendo is a medical technology company that develops and manufactures the GentleWave System, a technology platform for treating tooth decay by cleaning and disinfecting the interior spaces of teeth without removing tooth structure.
HardwareHealthtechMedical DevicesLaguna Hills, US
Bjarne Bergheim(Executive Officer, Director)inJohn McGaugh(Executive Officer)inJohn Bostjancic(Executive Officer)Hugh Neuharth(Executive Officer)Roy T. Chen(Chief Talent Officer)Chris Guo(Interim Chief Financial Officer)in
Co-investorsEssex Woodlands Healthcare PartnersGeneral AtlanticFjord VenturesMeritech Capital PartnersNeomed ManagementPura Vida Investments+1 more
Offers soft tissue repair solutions combining naturally sourced tissue with polymer; lead product OviTex for hernia repair (NASDAQ: TELA), based in Malvern, PA.
BiotechMalvern, US
Antony Koblish(Founder)inFrancis Conway(Executive Officer)Maarten Persenaire(Executive Officer)Christine Arasin(Executive Officer)
BoardKevin Rakin(Director)inAshley Freidman(Director)
Co-investorsCheckmate Capital Group LLCEssex Woodlands Healthcare PartnersHighCape CapitalSignet Healthcare Partners1315 CapitalRTW Investments L.P.
Traws Pharma is a pharmaceutical company developing therapeutics, with a leadership focus spanning oncology, infectious disease, and medical science areas.
BiotechHealthtech
Iain Dukes(Chief Executive Officer)inCharles Parker(Chief Financial Officer)C. David Pauza, PhD(Chief Science Officer)Robert R. Redfield, MD(Chief Medical Officer)Victor Moyo, MD(CMO Oncology)Nikolay Savchuk, PhD(Chief Operating Officer)
Verastem Oncology is a biopharmaceutical company that discovers and develops drugs to treat cancer patients.
BiotechMedical DevicesNeedham, US
Robert WeinbergRICHARD ALDRICH(Director)AMY C. CAVERS(Executive Officer)inCATHY CAREW(Executive Officer)inJONATHAN PACHTER(Executive Officer)inROB GAGNON(Executive Officer)in
Co-investorsBessemer Venture PartnersCardinal PartnersForesite CapitalLightstone VenturesLongwood FundOberland Capital+1 more
Verrica Pharmaceuticals is a therapeutics company developing and commercializing treatments for dermatological diseases, including molluscum contagiosum, common warts, and skin cancers such as basal cell and squamous cell carcinoma.
BiotechHealthtechMedical DevicesWest Chester, US
Noah Rosenberg(Executive Officer)inJohn Kirby(Executive Officer)Matthew Davidson(Executive Officer, Director)
BoardJayson Rieger(Executive Officer, Director)inPaul B. Manning(Director)inDavid Zawitz(Executive Officer)
Co-investorsPBM Capital
Alpheus is a clinical-stage biotechnology company developing Porphyrin Metabolite Activation (PoMA™), a drug-led oncology approach designed to treat glioblastoma using proprietary low-intensity ultrasound to activate tumor-localized porphyrin metabolites.
BiotechHealthtechMedical DevicesChanhassen, US
Jeremy Ling(Executive Officer)inSteve Weiner(Executive Officer)Vijay Agarwal(Founder, President and CEO)inWilliam Davis(Executive Officer, Director)
BoardImran Eba(Executive Officer)in
Board seatKlaus Veitinger· per SEC Form D
Co-investorsHealthQuest CapitalSamsara BioCapitalSV Health InvestorsAction Potential Venture Capital Ltd.BrightEdge
Perfuse Therapeutics develops novel ocular therapies for retinal and glaucoma diseases through drug delivery and formulation platforms.
BiotechHealthtechMedical DevicesSan Francisco, US
Sevgi Gurkan(Founder, Chief Executive Officer, and Member of the Board of Directors)in
BoardChristy Shaffer(Director)
Board seatChau Khuong· per SEC Form D
Co-investorsAccess BiotechnologyCatalio Capital Management, LPHatteras Venture PartnersLAVLilly Asia VenturesHatteras
ADARx is a clinical-stage biotechnology company developing RNA-targeted therapeutics designed to control the expression of disease-driving genes.
BiotechHealthtechMedical DevicesSan Diego, US
Zhen Li(Co-founder, President & CEO)inRui Zhu(Founding Member & Chief Technology Officer)Rob Ackles(Chief People Officer)inRyan Fisk(Chief Financial Officer & Chief Business Officer)inRobert A. MacLeod(Chief Scientific Officer)inChristopher Claeboe(Senior Vice President of Operations)in
Co-investorsBain Capital Life SciencesSR One Capital ManagementLilly Asia VenturesT. Rowe PriceAscenta CapitalTCG Crossover+3 more
Aer Therapeutics develops a science-driven therapeutic aimed at eliminating mucus plugs in the lungs to treat muco-obstructive lung diseases such as COPD and asthma.
BiotechHealthtechMedical DevicesRaleigh, US
Thomas Mathers(Executive Officer, Director)inJames Shaffer(Executive Officer, Director)John Fahy(Director)in
BoardChristy Shaffer(Director)inRishi Gupta(Director)inTim Shannon(Director)in
Co-investorsHatteras Venture PartnersCanaan PartnersPappas Capital
Alentis is a biotech company developing therapies for chronic liver disease, fibrosis, and cancer based on the molecular biology of liver disease.
AI & Machine LearningBiotechHealthtechMedical DevicesBasel, CH
Thomas Baumert(Founder)inMark Pruzanski(Chief Executive Officer)inLuigi Manenti(Chief Medical Officer)inJon Freve(Chief Financial Officer)inBryan Yoon(General Counsel and Chief Administrative Officer)inAditya Venugopal(Chief Business Officer)in
Co-investorsAvego BioScience CapitalBioMedPartnersFrazier Life SciencesJeito CapitalLongitude CapitalNovo Holdings+6 more
Aspen Neuroscience develops iPSC-derived autologous cell therapies for neurological diseases, with a lead product (ANPD001) in Phase 1/2a clinical trials for Parkinson's disease.
BiotechDeep TechDigital HealthMedical DevicesSan Diego, US
Andrés Bratt-Leal(Co-Founder and Senior Vice President, Research & Development)inANDRÉS BRATT-LEAL, Ph.D.(Co-Founder; Senior Vice President, Research & Development)Damien McDevitt(President and Chief Executive Officer)inDAMIEN MCDEVITT, Ph.D.(President and Chief Executive Officer)
Co-investorsARCH Venture PartnersLifeforce CapitalDomain AssociatesEDB InvestmentsSection 32Frazier Life Sciences+10 more
Brenig Therapeutics is a biotechnology company developing small-molecule therapies for Parkinson's disease and other neurodegenerative disorders, using AI-driven drug discovery.
AI & Machine LearningBiotechHealthtechDover, US
Megan McGill(Chief Executive Officer)inIain Dukes(Chief Business Officer / Chairman of the Board)inNikolay Savchuk(Chief Operating Officer)Tien Dam(Chief Medical Officer)in
Co-investorsNew Enterprise Associates (NEA)BGVTorrey Pines Investment
Congruence is a drug discovery company that applies protein dynamics, biophysics, machine learning, and computational chemistry to model proteins in their full dynamic state and predict disease correction in silico.
AI & Machine LearningBiotechDeep Tech
Clarissa Desjardins(Founder)in
Co-investorsAlexandriaDIMENSIONAngelini VenturesBDC Thrive Venture Fund for WomenLumira VenturesAmplitude Venture Capital+1 more
Corteria Pharma develops interceptive therapies aimed at treating subpopulations of patients with heart failure, sarcopenia, and obesity.
BiotechDigital HealthHealthtechLongevity
Philip JaniakinMarie-Laure OzouxinRégis OlivierinFrancesca C. LawsonMark KowalaEleonore Jouannyin
Co-investorsFountain Healthcare PartnersJeito CapitalKurma PartnersV-Bio VenturesOmnes CapitalInvivo Capital Partners+1 more
Entero Healthcare Solutions is a healthcare products distribution company operating in India, connecting pharmaceutical manufacturers with pharmacies and healthcare providers.
HealthtechLogistics & Supply Chain
Prem Sethi(Promoter, Whole-time Director & COO)inPrabhat Agrawal(Promoter, Managing Director & CEO)in
Enyo Pharma is a biotechnology company focused on drug development in the life sciences and therapeutics field.
BiotechHealthtechMedical DevicesLyon, FR
Jacky Vonderscher(Co-founder & CEO)inLaurène Meyniel-Schicklin(Founder, Head of Bioinformatics)inBenoît de Chassey(Founder, Head of Drug Discovery Platform)inPatrice André(Founder, Medical Advisor)inVincent Lotteau(Founder, Advisor)Jean-Jacques Garaud(Co-founder)in
Co-investorsAndera PartnersSofinnova PartnersBpifrance
Forward Therapeutics develops oral small-molecule medicines targeting inflammation-driven diseases, using a structure-based, data-driven discovery engine to design drugs against validated pathways.
AI & Machine LearningBiotech
Co-investorsCurie.Bio
Frontera Therapeutics is a biotechnology company engaged in therapeutic research and development, spanning translational medicine, clinical operations, and manufacturing.
BiotechDeep TechHealthtechBoston, US
Xinyan Li(CEO)
Co-investorsBoyu CapitalCreacion VenturesHongShan Capital Group6 Dimensions Capital
GentiBio develops engineered regulatory T-cell (EngTreg) therapies designed to reset the immune system and treat autoimmune and acute inflammatory diseases.
BiotechHealthtechMedical Devices
Jane Buckner(Scientific Co-founder (President, Benaroya Research Institute))Chandra Patel(Co-founder & SVP, Research and Development Operations)inDavid Rawlings(Scientific Co-founder and Senior Scientific Advisor)Andy Scharenberg(Scientific Co-founder, SAB Chair)Andy Walker(President and CEO)inTom Wickham(Chief Scientific Officer)
Co-investorsNovartis Venture FundJDRF T1D FundRA Capital
Gracell Biotechnologies develops cell therapy manufacturing platforms and treatments, with a focus on CAR-T cell therapies for cancer and autoimmune diseases.
BiotechHealthtechMedical DevicesSuzhou, CN
William Wei Caoin
Co-investorsLAVLilly Asia VenturesPivotal Life SciencesExome Asset ManagementJanus Henderson InvestorsRA Capital+3 more
i2020 Accelerator (T123 LLC) is a drug discovery accelerator that de-risks early-stage science and advances drug discovery platforms toward lead and clinical candidate stage within roughly two years, working across therapeutic areas such as oncology, immunology, and infectious diseases.
BiotechDeep TechHealthtechSan Diego, US
Co-investorsTorrey Pines InvestmentBioGeneration VenturesBGV
iECURE is a clinical-stage biotechnology company developing in vivo genome editing therapies that insert a functional copy of a gene into a patient's genome to treat rare, life-threatening genetic diseases in children.
BiotechHealthtechMedical Devices
James M. Wilson(Scientific Founder)Joseph Truitt(CEO & Board Member)inPaul Firuta(COO)inAlex Monteith(Chief Business Officer)David Garrett(CFO)inGabriel M. Cohn(Chief Medical Officer)in
Co-investorsLYFE CapitalVersant Ventures
Insilico Medicine uses artificial intelligence to discover and develop new drugs, operating an AI-driven platform for pharmaceutical research and development.
AI & Machine LearningBiotechDigital HealthHealthtechHong Kong, US
Aleksandrs Zavoronkovs(Executive Officer, Director)Alex Zavoronkov(Director)Alex Zhavoronkov(Founder)inAlex Aliper(President)inFeng Ren(Chief Scientific Officer, Executive Director & Co-CEO)in
BoardNisa Leung(Director)in
Co-investorsLilly Asia VenturesQiming Venture PartnersWarburg PincusBaidu VenturesEight Roads VenturesLake Bleu Capital+13 more
Lattice Medtech distributes medical devices and offers strategic manufacturing and full-service distribution partnerships for medical device companies.
HealthtechLogistics & Supply ChainMedical Devices
Rahul Garg(CEO & Founder)Rahul Bagaria(CFO)
MDClone provides a healthcare data platform that uses synthetic data to support clinical research and care-improvement initiatives, used by health systems such as Intermountain for programs targeting chronic conditions like kidney disease, diabetes, and cardiovascular disease.
AI & Machine LearningData & InfrastructureDigital HealthHealthtech
Ziv Ofek(Co-Founder and President)inBruno Lempernesse(Chief Executive Officer)inAaron Galaznik(Chief Medical Officer)inAlmog Ohayon(Chief Product and Technology Officer)in
Co-investorsaMoonLightspeed Venture PartnersWarburg PincusDeclaration PartnersViola Ventures
MinervaX is a biotech company developing prophylactic vaccines, with therapeutic focus areas including immunology and infectious disease.
BiotechHealthtech
PerBengt(CSO)
Co-investorsAdjuvant CapitalIndustrifondenPureos BioventuresSanofi VenturesSunstone CapitalEQT Life Sciences+2 more
OnCusp Therapeutics develops oncology therapeutics for cancer treatment, including antibody-drug conjugates and small molecule compounds in clinical and preclinical stages.
BiotechMedical DevicesNew York, US
Dr. Bing Yuan(Co-Founder, Chief Executive Officer)Dr. Eric Slosberg(Co-Founder, Chief Development Officer)Dr. Andy Fu(Co-Founder, Chief Business Officer)Bing Yuan, Ph.D., MBA(Co-Founder, Chief Executive Officer)Eric Slosberg, Ph.D.(Co-Founder, Chief Development Officer)Andy Fu, PharmD, MBA(Co-Founder, Chief Business Officer)
Co-investorsCatalio Capital Management, LPF-Prime CapitalSofinnova VenturesDe Novo VenturesInsight PartnersNVIDIA
Ottimo is a biotech company developing oncology and immuno-oncology therapeutics, including antibody-based cancer treatments.
BiotechHealthtech
Jonny Finlay(Founder and Chief Scientific Advisor)David Epstein(Chair & Chief Executive Officer)inMehdi Shahidi(Head of Development & Chief Medical Officer)Ling Zeng(General Counsel and EVP of Execution)inSpencer Fisk(Chief Technical and Quality Officer)
Co-investorsMedicxiSamsara BioCapitalAvoro Capital AdvisorsJMI Equity
QuantX Bio applies a proprietary computational platform to accelerate the discovery and optimization of drug candidates.
AI & Machine LearningBiotechDeep Tech
Co-investorsSanofi VenturesCreacion VenturesLilly Asia Ventures
Sirius Therapeutics is a biopharmaceutical company developing siRNA-based therapeutics, including work in the anti-coagulant therapeutic area.
BiotechHealthtechLongevityMedical DevicesSan Diego, US
Qunsheng Ji(Chief Executive Officer)Curt Bradshaw(Chief Scientific Officer)Patrick Yue(Chief Medical Officer)Hailei Lu(Chief Financial Officer)
Co-investorsDelos CapitalCreacion Ventures
Uquifa is a supplier of active pharmaceutical ingredients and related products for the human and animal health markets, emphasizing quality standards and regulatory compliance.
Advanced ManufacturingBiotechHealthtechNew MaterialsBarcelona, ES
Saurabh Gurnurkar(Managing Director & CEO, Uquifa Group)inPilar Valle(Chief Financial Officer)inAlfred Pascual(Corporate Manufacturing Operations Director)inPéter Ács(General Manager & Chief Operating Officer – Soneas Chemicals Ltd.)
Variantyx is a molecular diagnostics company offering genetic testing for rare genetic disorders, reproductive genetics, and precision oncology.
AI & Machine LearningBiotechDigital HealthHealthtechFramingham, US
Haim Neerman(Co-founder)inTomer Jackman(Co-founder & VP Customer Support and Lab Services)inJeffrey Weisberg(Chief Financial Officer)inYaron Rachmany(Operations, R&D, IT (executive))inChristine Stanley(Chief Genomics and Compliance Officer)inEyal Reinstein(Chief Medical Officer)in
Co-investors20/20 HealthCare Partners LLCBosch VenturesNew Era Capital PartnersPeregrine VenturesPitangoQuark Venture Inc.+2 more
Whale Imaging is a medical imaging company.
HardwareHealthtechMedical DevicesBoston, US
Sean Z.(Founder)in
Co-investorsSequoia Capital
HealthtechCarlsbad, US
Christoph Scharf(Director)inRandy Werneth(Executive Officer, Director)Graydon Beatty(Executive Officer)inVince Burgess(Director)inJohn Dahldorf(Executive Officer)
BoardAditya Puri(Director)
Board seatDavid Bonita· per SEC Form D
Co-investorsAdvent Life SciencesXeraya CapitalDeerfield Management CompanyFormation GroupGE VenturesIndex Ventures
Adela develops blood-based tests for cancer detection using epigenetics and liquid biopsy technology, aimed at helping patients and clinicians detect and act on cancer earlier.
BiotechDigital HealthHealthtechMedical DevicesFoster City, US
Daniel Diniz De Carvalho(Executive Officer, Promoter)Scott Bratman(Executive Officer, Director)inAnne-Renee Hartman(Founder)inAlan Williams(Executive Officer)inLisa Alderson(Executive Officer, Director)inPriscilla Huang(Executive Officer)in
Board seatDavid Bonita· per SEC Form D
Co-investorsDecheng CapitalF-Prime CapitalDeerfield Management CompanyMenlo Ventures
BiotechCincinnati, US
Robert Shalwitz(Executive Officer)Joseph Gardner(Founder)inDuane Nash(Director)Kevin Peters(Executive Officer)Steve Pakola(Executive Officer)Ian A.W. Howes(Executive Officer)
Board seatChau Khuong· per SEC Form D
Co-investorsCincyTechSofinnova VenturesAlly Bridge Group
Angiex develops Nuclear-Delivered Antibody-Drug Conjugate (ND-ADC) therapies for solid cancers, using a platform that delivers chemotherapeutic payloads to the nucleus of tumor cells and tumor blood vessel endothelial cells.
BiotechHealthtechMedical DevicesCambridge, US
Paul Jaminet(Founder & CEO)inShou-Ching Jaminet(Founder, Scientific Adviser)Hal Dvorak(Founder, SAB Chair)
BoardErrik Anderson(Director)Jason Camm(Director)in
Board seatIain Dukes· per SEC Form D · $28.4M raise · filed Sep 2025
Co-investorsGaingelsGreen Meadow VenturesK5 GlobalMana Ventures
__Twitter.png)
BiotechSan Francisco, US
Matthew Patterson(Executive Officer, Director)in
BoardSteve Squinto(Director)inKush Parmar(Director)inJonathan Leff(Director)Thomas Woiwode(Director)
Board seatJonathan Silverstein· per SEC Form D · filed Sep 2015
Co-investorsAsset Management CompanyRA CapitalvenBio Partners5AM VenturesDeerfield Management CompanyVenrock
Averna Therapeutics is a biotechnology company developing therapeutics.
BiotechDeep TechHealthtechMedical DevicesWatertown, US
Richard Morris(Chief Financial Officer)inThomas M. Barnes(CEO & Board Member)
BoardRoy Amariglio(Director)Nick Olsen(Director)inMichal Silverberg(Director)in
Board seatStephen Squinto· per SEC Form D
Co-investorsDeep InsightDelos CapitalNovartis Venture FundARC VENTURESInsight Partners
Belenos Biosciences develops long-acting bispecific antibody therapeutics for chronic inflammatory diseases such as COPD, asthma, atopic dermatitis, CRSwNP, and CSU.
BiotechHealthtechNew York, US
Donnie McGrath(CEO & Co-Founder)Megan Dow(COO & Co-Founder)Tania Dimitrova(CFO & Co-Founder)Glenn Rosen(Chief Translational Officer & Co-Founder)Donnie McGrath, M.D., M.P.H.(CEO & Co-Founder)inMegan Dow, Ph.D.(COO & Co-Founder)in
Board seatCarl Gordon· per SEC Form D
Cerapedics develops P-15 peptide enhanced bone graft products, marketed as bone growth accelerators, for spinal fusion procedures.
BiotechHealthtechMedical DevicesWestminster, US
Andrew J. Tofe(Director)inBritt Pearson(Executive Officer)inJeff Marx(Executive Officer)inGlen Kashuba(Executive Officer, Director)inJerome Connor(Executive Officer)inAndrew Handwerker(Executive Officer)
Board seatChau KhuongJonathan Silverstein· per SEC Form D
Co-investorsRevelation PartnersNGN Capital
Chemomab is a clinical-stage biotech developing therapies that target the CCL24 cytokine involved in fibro-inflammatory diseases, with its lead antibody nebokitug tested in conditions including primary sclerosing cholangitis, systemic sclerosis, MASH and idiopathic pulmonary fibrosis.
BiotechHealthtechTel Aviv
Adi Mor(Executive Officer, Director)inAdi Mor George(Executive Officer, Director)Jill Quigley(Director)inSigal Fattal(Executive Officer)inMatthew Frankel(Executive Officer)inArnon Aharon(Executive Officer)in
Board seatStephen Squinto· per SEC Form D
Co-investorsAltium CapitalSBI JI Innovation Advisory Ltd.
Convergent Therapeutics develops radioantibody-based (PSMA-targeted) therapies for cancers, including metastatic castration-resistant prostate cancer (mCRPC).
BiotechHealthtechCambridge, US
Philip Kantoff(Chief Executive Officer, Co-Founder)inNeil Bander(Senior Scientific Advisor, Co-Founder)Alexander Brown(Executive Officer)inAndrew Davis(Chief Business and Strategy Officer)inElizabeth L. Montgomery(Chief People Officer)inEric M. Sullivan(Chief Financial Officer)in
Board seatTal Zaks· per SEC Form D
Co-investorsInvusRA Capital
Enlaza Therapeutics develops covalent protein therapeutics using its War-Lock technology, which incorporates proprietary unnatural amino acids into protein drugs so they form irreversible covalent bonds with disease-related targets.
BiotechDeep TechSan Diego, US
Sergio Duron(Co-Founder & Chief Executive Officer)inSanford Madigan(Co-Founder, President & Chief Business Officer)inAnaleah Heidt(Chief Scientific Officer)in
BoardMarcos Milla(Director)inJay Lichter(Director)inTighe Reardon(Executive Officer)
Board seatStephen Squinto· per SEC Form D · $15M raise · filed Sep 2025
Co-investorsFrazier Life SciencesLightspeed Venture PartnersSamsara BioCapitalAvalon BioVenturesPappas CapitalPfizer Venture Investments+1 more
Precision medicine company developing therapeutics for genetically-defined age-related macular degeneration.
BiotechCambridge, US
James McLaughlin(Executive Officer, Director)in
BoardJean George(Director)Jason Rhodes(Director)in
Board seatCarl Gordon· per SEC Form D
Co-investorsAltium CapitalLightstone VenturesAtlas Venture
Genetic medicines company developing targeted nucleic acid therapeutics via a gene monoclonal antibody platform.
BiotechPennington, US
Chris Duke(Mr. Duke is the Chief Operating Officer of the Issuer.)inDale Ludwig(Mr. Ludwig is the Chief Scientific Officer)inAnuj Goswami(Mr. Goswami is the General Counsel and Secretary)inClaudine Prowse(Ms. Prowse is the Chief Financial Officer)inGary Sender(Director)Julie Hambleton(Director)
Board seatChau Khuong· per SEC Form D
Inspire Medical Systems develops an FDA-approved implantable device that treats obstructive sleep apnea (OSA) by working with the patient's natural breathing, controlled via a small remote and intended for patients for whom CPAP is not effective.
Digital HealthHealthtechMedical DevicesGolden Valley, US
Tim Herbert(Founder)in
BoardMudit Jain(Director)Joyce Erony(Director)inDana Mead(Director)Casey Tansey(Director)
Board seatChau Khuong· per SEC Form D · $37.5M raise · filed Nov 2016
Co-investorsAmzak HealthAPERTURE Venture PartnersUS Venture Partners
Neurogastrx is a biopharmaceutical company developing therapies for patients with gastrointestinal disorders.
BiotechHealthtechWoburn, US
Cyril De Colle(Founder)inJAMES DETORE(Executive Officer)JAMES O'MARA(Executive Officer, Director)inPAUL ROGERS(Executive Officer)in
BoardDAVID ALLISON(Director)in
Board seatKevin KochKlaus Veitinger· per SEC Form D
Co-investors5AM VenturesSamsara BioCapitalvenBio PartnersVivo CapitalRTW Investments L.P.venBio Global Strategic+1 more
Noctrix Health develops clinically validated wearable therapeutics for managing chronic neurological disorders, with its first product Nidra receiving FDA De Novo authorization and dedicated CMS HCPCS codes.
Digital HealthMedical DevicesWellness & FitnessPleasanton, US
Shri Raghunathan(Founder)inShriram Raghunathan(Executive Officer, Director)
BoardAllan May(Director)Mudit Jain(Director)inTracy Pappas(Director)in
Board seatChau Khuong· per SEC Form D
Co-investorsAngelini VenturesBlue Venture FundsJoyance PartnersTreo Ventures, LlcZühlke VenturesBridge Bank+2 more
BiotechBoston, US
Darlene Deptula-Hicks(Executive Officer)inStephen S. Yoder(Executive Officer, Director)inDarlene M. Deptula-Hicks(Acting Chief Financial Officer)in
BoardChristina Takke(Director)Steven Prelack(Director)
Board seatChau Khuong· per SEC Form D · $16.5M raise · filed Jun 2016
Co-investorsRidgeback CapitalBiotechnology Value FundFrazier Life Sciences
Promentis Pharmaceuticals is a privately-held biopharmaceutical company developing oral compounds targeting the System xc- glutamate pathway to treat neuropsychiatric disorders.
BiotechHealthtechMental HealthMilwaukee, US
David Baker, PhD(Director)Daniel Lawton(Executive Officer, Director)Tom Beck(Executive Officer, Director)Chad Beyer(Executive Officer)Chad E Beyer, PhD(Executive Officer, Director)
Board seatKlaus Veitinger· per SEC Form D · $6M raise · filed Dec 2019
Co-investorsAisling CapitalF-Prime Capital
Rhythm Therapeutics develops precision medicines for rare neuroendocrine diseases, particularly those affecting the melanocortin-4 receptor pathway.
BiotechDigital HealthHealthtechMedical DevicesBoston, US
Keith Gottesdiener(Executive Officer, Director)inBart Henderson(Mr. Henderson is the President and Treasurer of the Issuer.)inDavid Meeker(President and Chief Executive Officer)in
BoardEdward T. Mathers(Director)inNeil Exter(Director)in
Board seatJonathan Silverstein· per SEC Form D · $40M raise · filed Dec 2015
Co-investorsForesite CapitalHEALTHCARE ROYALTY PARTNERSNew Enterprise Associates (NEA)Pfizer Venture InvestmentsWellington ManagementThird Rock Ventures
Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted therapies for cardiometabolic disease.
BiotechHealthtechMedical DevicesPortland, US
Robert Jacks(Executive Officer, Director)inDavid Aaron Katz(Executive Officer, Director)
BoardJonathan Root(Director)inNiall O'Donnell(Director)inZach Scheiner(Director)in
Board seatKlaus Veitinger· per SEC Form D
Co-investorsRA CapitalRiverVest Venture PartnersUS Venture PartnersForbion
BiotechCambridge, US
William C. Shakespeare(Director)in
BoardIain Dukes(Executive Officer, Director)inMichael Rome(Director)in
Board seatCarl Gordon· per SEC Form D
Co-investorsForesite CapitalLongitude CapitalNextech InvestNexTech VenturesOmega FundsPontifax Venture Capital+2 more
Thrombolex develops endovascular catheters using pharmaco-mechanical technology to treat arterial and venous thromboembolic (A+VTE) conditions by dissolving blood clots.
BiotechHealthtechMedical DevicesKingston, US
Riyaz Bashir(Innovator / Creator of BASHIR Endovascular Catheters)John Cerminaro(Executive Officer)inMichael J. Cerminaro(Executive Officer, Director)inMarvin Woodall(Executive Officer, Director)Brian G. Firth(Executive Officer, Director)Todd Richmond(Director)
Board seatDavid Bonita· per SEC Form D
Co-investorsDelaware Crossing Investor Group
Treeline develops therapeutics focused on oncology, leveraging insights from clinical practice and laboratory research.
AI & Machine LearningBiotechHealthtechMedical DevicesWatertown, US
Joshua H. Bilenker(Executive Officer, Director, Promoter)Jeffrey Engelman(Executive Officer, Director, Promoter)inJosh Bilenker(Founder)inJosh Bilenker Jeff Engelman(Founder)
BoardKristina Burow(Director)inAli Satvat(Director)
Board seatDavid Bonita· per SEC Form D
Co-investorsAisling CapitalARCH Venture PartnersGV (Google Ventures)ARC VENTURESCasdin CapitalExor+3 more
BiotechSouth San Francisco, US
Gerrit Klaerner(Executive Officer, Director)Melissa Miksch(Executive Officer)
BoardSandra Coufal(Director)Robert Alpern(Director)
Board seatKlaus VeitingerDavid Bonita· per SEC Form D
Co-investorsAvoro Capital AdvisorsLongitude CapitalWellington ManagementFrazier Life SciencesHercules Capital, Inc.
Vanqua Bio is a biotechnology company developing molecules intended to become medicines for neurodegenerative disorders, including Parkinson's disease, Alzheimer's disease, and related neurological conditions.
BiotechDeep TechHealthtechLongevityChicago, US
Rand Sutherland(Director)inJim Sullivan(CEO)inKevin Hunt(CSO)in
BoardBernard Davitian(Director)Uya Chuluunbaatar(Director)
Board seatJonathan SilversteinStephen SquintoMona Ashiya· per SEC Form D
Co-investorsAvoro Capital AdvisorsOUP (Osage University Partners)Pontifax Venture CapitalCasdin CapitalOmega Funds
ViewRay develops MRIdian A3i, an MRI-guided radiation therapy system that uses diagnostic-quality MRI imaging for real-time tissue tracking and automated beam control during cancer treatment.
HardwareHealthtechMedical DevicesOakwood Village, US
James F. Dempsey(Executive Officer, Director)inDavid Chandler(Mr. Chandler is the Chief Financial Officer of the Issuer.)Chris A. Raanes(Executive Officer, Director)Michael Brandt(Executive Officer)D. David Chandler(Executive Officer)Gregory M. Ayers(President and Chief Executive Officer of the Issuer.)
Board seatDavid Bonita· per SEC Form D · filed Aug 2015
Co-investorsAisling CapitalF-Prime CapitalXeraya Capital
46 Capital is an investment firm focused on early-stage companies across multiple sectors, led by experienced professionals with backgrounds in venture capital, private equity, healthcare, energy, and finance.
Fintech
Tim Clark(Managing Director)
Co-investorsHurricane VenturesAndreessen HorowitzAscenta CapitalAvaana CapitalBoxGroupClaypond Capital+7 more
Adcendo develops antibody-drug conjugates (ADCs) targeting cancers with high unmet medical need.
BiotechMedical DevicesCopenhagen, DK
Michael Pehl, MSc(Chief Executive Officer)
Co-investorsVida VenturesHealthCapJeito CapitalNovo HoldingsPontifax Venture CapitalRA Capital+3 more
Adimab develops proprietary platforms for antibody and protein therapeutic discovery, engineering fully-functional immunoglobulins in a controllable in vitro eukaryotic system.
AI & Machine LearningBiotechDeep TechVermont, US
Co-investorsGrandBanks CapitalLaunchCapitalLux CapitalMithril Capital ManagementPremji InvestSV Health Investors+1 more
Advanced Enzymes is a company in the enzyme/biotech industry; the page shown is an investor relations section with quarterly financial results, shareholding patterns, and corporate governance reports.
BiotechFoodTechNew Materials
Aerin Medical develops non-invasive radiofrequency treatment systems for chronic nasal conditions, offering the VivAer stylus for nasal airway obstruction and RhinAer stylus for chronic rhinitis.
HealthtechMedical DevicesMountain View, US
Matt Brokaw(CEO & President)inDerrick Sung(Executive Officer)inMatthew Salkeld(Executive Officer)Irina Ridley(Executive Officer)inAndre Cheng(Executive Officer)inFred Dinger(Executive Officer, Director)in
Co-investorsLaunchCapitalQuesta CapitalTargeted Technology FundsAlly Bridge GroupHorizon
Clinical-stage biopharmaceutical company developing novel inhaled therapies for COPD.
BiotechPalo Alto, US
James Li(Executive Officer, Director)Maria Fardis(Executive Officer, Director)in
BoardAnna Chen(Director)Colin Walsh(Director)Evan Caplan(Director)Jill Carroll(Director)in
Co-investorsFrazier Life SciencesLongitude CapitalSR One Capital Management
AirStrip develops clinical decision support and patient monitoring software, including data-driven and AI predictive analytics tools, for hospitals, health systems, and clinicians.
AI & Machine LearningDigital HealthHealthtechMedical DevicesSaaSSan Antonio, US
Alan Portela(Executive Officer, Director)inDr. Naseem(Chief Executive Officer)Lauren Schiegg(Chief Operating Officer)inHari Radhakrishnan(Chief Medical Officer)inSken Huang(Chief Financial Officer)inRory(Chief Commercial Officer)
AK Medical is a company providing investor and corporate information, headquartered in Beijing with a principal place of business in Hong Kong.
Advanced ManufacturingHardwareHealthtechMedical DevicesBeijing, CN
Co-investorsDecheng Capital
BiotechSeattle, US
Mitchell Gold(Executive Chairman and Chief Executive Officer)inMichael Kornacker(Executive Officer, Director)inRyan Swanson(Executive Officer, Director)inDavid Miller(Executive Officer, Director)inJames Paul Rickey(Senior Vice President and Chief Financial Officer)Mark James Litton(President and Chief Operating Officer)
Co-investorsDecheng CapitalFrazier Life SciencesBiotechnology Value Fund
Alterome is a clinical-stage precision oncology company developing small-molecule, alteration-specific cancer therapies, with two internally discovered drug candidates in the clinic.
AI & Machine LearningBiotechDeep TechSan Diego, US
Eric A. Murphy(Executive Officer, Director, Promoter)inRyan B. Corcoran(Director, Promoter)Richard Heyman(Founder)
BoardThilo Schroeder(Director)inCarl Gordon(Director)inArjun Goyal(Director)in
Co-investorsCanaan PartnersNextech InvestVida VenturesDigitalis VenturesNVIDIA
Altis Labs provides a web-based platform that applies AI models to medical imaging data to generate reproducible predictions and quantifications for clinical trials.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesToronto, CA
Felix Baldauf-Lenschen(Founder & CEO)inJohn(CTO)
Co-investorsCreative Destruction Lab (CDL)Debiopharm Innovation FundFusionBenchstrength Partners
Developing therapeutic peptides targeting rare endocrine diseases (past investment).
Co-investorsAndera PartnersATEM Capital FundCTI Life Sciences Fund L.P.EQT Life SciencesKurma PartnersOctalfa+4 more
AnchorDx develops, manufactures, and sells cancer early-screening and diagnostic products based on ctDNA methylation high-throughput sequencing, along with related testing services covering over 70% of high-incidence cancers such as lung, breast, digestive, and urinary cancers.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesGuangzhou, CN
范建兵(Founder)
Co-investorsMarathon Venture Partners6 Dimensions Capital
Angitia Bio is a biopharmaceutical company developing therapies for musculoskeletal and related diseases.
Biotech
Co-investorsAscenta CapitalFrazier Life SciencesRA CapitalWellington ManagementFrazier
Arcatron designs and sells mobility and assistive products under the Frido brand, including electric and manual wheelchairs, mobility scooters, transfer lifts, walking aids, shower and hygiene aids, and bath mats.
ConsumerE-commerceMedical Devices
Dewaj Baruah(Founder)in
Co-investorsJetty Ventures
Architect Therapeutics is a drug discovery company that uses C-H bond activation chemistry to synthesize novel 3D small-molecule scaffolds and screen them against difficult-to-drug targets.
BiotechDeep TechSan Diego, US
Jin-Quan Yu(Founder)inJin-Quan Yu, Ph.D.(Scientific Founder)Ben Cravatt Ph.D.(Scientific Founder)Rich Heyman, Ph.D.(Scientific Founder)Angie You, Ph.D.(Chief Executive Officer)
Co-investorsFrazier Life SciencesViking Global
ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing medicines for difficult-to-treat diseases, starting with cancers.
BiotechHealthtechMedical DevicesNewtown Square, US
Zhengbin (Bing) Yao(Executive Officer, Director)inBrent Rice(Chief Commercial Officer)in
BoardJason Zhang(Director)Cong Xu(Director)Stuart Lutzker(Director)
Co-investorsCatalio Capital Management, LPForesite CapitalGeneral CatalystHBM Healthcare InvestmentsHBM PartnersHongShan Capital Group+4 more
.png)
ARS Pharmaceuticals is a biopharmaceutical company developing treatments for severe allergic reactions, with a focus on patient-friendly, easy-to-use intranasal therapies.
BiotechHealthtechMedical DevicesSan Diego, US
Richard Lowenthal(Executive Officer, Director)inPratik Shah(Director)
BoardJonathan Leff(Director)
Co-investorsNextech InvestRA CapitalSR One Capital ManagementSofinnova Ventures
BiotechBuffalo, US
Flint Besecker(Executive Officer, Director)inLi Shen(Executive Officer)inSimon Pedder(Executive Officer)inJohnson Lau(Executive Officer, Director)inWilliam Zuo(Executive Officer)Rudolf Kwan(Executive Officer)
Co-investorsAvoro Capital AdvisorsSalica Investments
Augmedix builds AI-driven documentation technology for clinicians, aiming to reduce time spent on technology so providers can focus on patient care.
AI & Machine LearningDigital HealthHealthtechSan Francisco, US
Ian Shakil(Executive Officer, Director)inPelu Tran(Cofounder)inEmmanuel Krakaris(Executive Officer, Director)inPaul Ginocchio(Executive Officer)inSandra Breber(Executive Officer)inJoseph Marks(Director)
Co-investorsDCM VenturesEvolution VC PartnersGaingelsGreat Oaks Venture CapitalLifeSci Venture PartnersOVO Fund+4 more
Avedro is an ophthalmic company focused on corneal health, known for bio-activated cross-linking therapies such as the KXL system and riboflavin-based treatments used to address progressive keratoconus.
BiotechHealthtechMedical DevicesWaltham, US
David F. Muller(Executive Officer, Director)inBrian J. Roberts(Executive Officer)inRhonda J. Bracey(Executive Officer)inThomas W. Burns(Chairman & Chief Executive Officer)
BoardJason Hong(Director)Jeff Dykan(Director)in
Co-investorsAPERTURE Venture PartnersLAVLilly Asia VenturesSCP Vitalife PartnersThird Point VenturesWestern Technology Investment+5 more
Avenzo Therapeutics is a clinical-stage biopharmaceutical company developing therapeutic treatments.
BiotechSan Diego, US
Athena Countouriotis(Co-Founder, Chief Executive Officer)Mohammad Hirmand(Executive Officer)inPaolo Tombesi(Executive Officer)inScott Lipman(Executive Officer)inBrian Sun(Executive Officer)in
BoardCarl Gordon(Director)
Co-investorsDelos CapitalForesite CapitalINCE CapitalLongwood FundNew Enterprise Associates (NEA)Quan Capital+6 more
Biotechnology company developing immunomodulators using a HALOS nanotechnology platform for chronic inflammation.
BiotechDigital HealthHealthtechMedical DevicesCambridge, US
Michael Tolentino(Executive Officer, Director)inMohamed A. Genead(Chairman & CEO)inDavid Callanan(Executive Officer)inDerek Kunimoto(Executive Officer)inJeffrey Nau(Chief Executive Officer)inTarek S. Hassan(Chief Development Officer)in
Co-investorsJeito CapitalLongitude CapitalCatalio Capital Management, LPAvoro Capital AdvisorsDigitalis VenturesOmega Funds
Repligen provides bioprocessing technologies—including process intensification, tangential flow filtration, chromatography, process analytics, and single-use fluid management—for upstream and downstream biopharmaceutical workflows.
BiotechHardwareMedical DevicesLebanon, US
Tillman Gerngross(Director)Errik Anderson(Director)inWarren Kett(Executive Officer)Jon Sheller(Executive Officer)Kevin Issett(Executive Officer, Director)Kevin Isett(Executive Officer, Director)
Co-investorsSV Health InvestorsBorealis VenturesMithril Capital ManagementNeomed ManagementPolaris PartnersSands Capital Ventures+1 more
Azura is an onchain trading platform that lets users trade any onchain asset using USD without bridging, gas, or wallet management, at zero fees.
Crypto & Web3Fintech
Co-investorsAlliance DAO (ex DeFi Alliance)De Fi Alliance HoldingsInitialized CapitalThanefield CapitalTranspose Platform ManagementRaj Gokal+2 more
Azura Ophthalmics develops a new therapeutic class of ophthalmic keratolytics aimed at treating lid margin and ocular surface diseases and other underserved ophthalmic conditions.
BiotechHealthtechMedical Devices
Luba(Director of Pre-Clinical Development)
Co-investorsBrandon Capital
Manufactures surgical instrument sets and tools for orthopedic procedures such as hip arthroscopy, including curettes, probes, rasps, tissue elevators, and suture manipulation devices.
HardwareHealthtechMedical DevicesSports Tech
BH Therapeutics is a drug development company that uses structure-based rational drug design to identify structural limitations in existing therapies and design novel chemical scaffolds to address them.
Biotech
J. Jean Cui, Ph.D.(Scientific Founder, President and CEO)Y. Peter Li, Ph.D., MBA(Cofounder and Executive Chairman)
Co-investorsVivo Capital
binx health develops FDA-cleared, CLIA-waived point-of-care diagnostic testing for chlamydia and gonorrhea in male and female patients, delivering central-lab-quality results in about thirty minutes so patients can test, get diagnosed, and receive treatment in one visit.
BiotechDigital HealthHealthtechMedical DevicesTrowbridge
Anna Dixon(Executive Officer)inMarc Jones(Executive Officer)inJeffrey R. Luber(Executive Officer, Director)in
BoardAndrew Goldman(Director)Martin Munchbach(Director)Jihua Wang(Director)
Co-investorsAsabys Partners
Biobeat develops a cuff-less, ambulatory blood pressure monitoring system built around a proprietary PPG sensor and a platform for tracking vital signs, aimed at helping physicians diagnose and manage hypertension.
Digital HealthHealthtechMedical Devices
Arik B.(Founder)inArik Ben Ishay(Founder & CEO)Johanan May(Founder, SVP & CTO)inIsrael Sarussi(Founder, SVP R&D)inMichael Gioffredi(CCO)in
BoardRaymond W. Cohen(Chairman of the Board)
Co-investorsAlly Bridge GroupRaptor Group
Biohaven is a biopharmaceutical company that discovers, develops, and commercializes treatments across immunology, obesity, neuroscience, and oncology, targeting rare and common diseases with limited treatment options.
BiotechHealthtech
Vlad Coric(Chairman & Chief Executive Officer)in
Co-investorsAisling CapitalAPERTURE Venture PartnersConnecticut InnovationsOUP (Osage University Partners)HBM Healthcare Investments
Leading provider of orthopedic products to the Chinese healthcare market.
Co-investorsLegend Capital
Braveheart develops treatments for hypertrophic cardiomyopathy and related cardiac conditions.
BiotechDigital HealthHealthtechMedical Devices
Travis Murdoch, M.D.(Chief Executive Officer and Board Director)in
Co-investorsAndreessen HorowitzFrazier Life SciencesForbion
CandidRx develops T-cell engager antibodies to treat autoimmune diseases by redirecting T-cells to eliminate autoreactive B-cells.
BiotechHealthtechSan Diego, US
Ken Song(Chairman, President and CEO)inKenneth Song, M.D.(Executive Officer, Director)Arvind Kush(Executive Officer)Timothy Lu, M.D.(Executive Officer)inBernie Huyghe, Ph.D.(Executive Officer)
BoardJeffrey Tong, Ph.D.(Director)
Co-investorsForesite CapitalLifeSci Venture PartnersSamsara BioCapitalTCG CrossoverThird Rock VenturesvenBio Partners+2 more
Carrot is a global fertility and family-building platform that provides access to fertility care, maternity support, and family-building guidance for individuals and families.
FemTechHealthtechHR TechSan Francisco, US
Asima Ahmad(CMO)inTammy Sun(CEO, co-founder)inDavid Utley(Executive Officer, Director)Dr. Asima Ahmad(Founder)Arun VenkatesanMaxwell Radomsky
Co-investors515 VenturesAll TurtlesAurumBackstage CapitalCore Venture CapitalCRV (Charles River Ventures)+18 more
Cellipont Bioservices is a contract development and manufacturing organization (CDMO) that provides GMP manufacturing and development services for advanced cell therapies.
Advanced ManufacturingBiotechHealthtechThe Woodlands, US
Avalo is a clinical-stage biotechnology company developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases.
BiotechMedical DevicesBaltimore, US
Blake M. Paterson(Executive Officer, Director)Mariam Morris(Executive Officer)inRonald Marcus(Executive Officer)inUli Hacksell(Executive Officer, Director)John Kaiser(Executive Officer)inJames Vornov(Executive Officer)in
Co-investorsNew Enterprise Associates (NEA)
Charm is a payments and savings app that enables users to send money across different platforms (Venmo, Cash App, Zelle) through a unified interface, with funds earning interest when held in the app.
ConsumerCrypto & Web3FintechSocialNew York City, US
Gray Newfield(Founder)inNoah Newfield(Founder)inChristian Rocha(Founder)Toby Padilla(Founder)
Co-investorsPioneerY Combinator468 CapitalCavalry VenturesF-Prime CapitalFirestreak Ventures+7 more
Charm builds open-source tools and libraries for creating user interfaces and applications in the terminal, including command-line interface frameworks, markdown readers, and components for developers.
Developer Tools
Co-investorsBetaworksCavalry VenturesFelix JahnGradient VenturesLowercarbon CapitalMotive Force+6 more
Charm.fi is a decentralized finance platform offering automated liquidity management vaults on Ethereum, letting users browse or create vaults for any token and build LP strategies to manage liquidity and earn yields.
Crypto & Web3Fintech
Co-investorsCoinbase VenturesCavalry VenturesF-Prime CapitalFuel CapitalGradient VenturesKhosla Ventures+2 more
.png){kind=avatar}
CHARM is a biotech company developing a next-generation menin inhibitor for acute myeloid leukemia (AML), designed to address resistance seen with first-generation approaches.
AI & Machine LearningBiotechHealthtechLondon
Lakshyaditya Singh Aithani(Executive Officer, Director)David Baker(Founder)Laksh Aithani(Founder)
BoardRishi Gupta(Director)inNihal Sinha(Director)inMuzammil Mansuri(Director)in
Co-investorsF-Prime CapitalNew Enterprise Associates (NEA)NVIDIASR One Capital ManagementAxial VCKhosla Ventures+1 more
BiotechChelsea, US
RICHARD BATYCKY(Executive Officer)GLENN BATCHELDER(Director)BRYAN STUART(Executive Officer)inMARK IWICKI(Executive Officer, Director)inMARTIN FREED(Executive Officer)in
BoardROB HOPFNER(Director)in
Co-investorsCanaan PartnersLongitude CapitalSofinnova VenturesBay City CapitalFountain Healthcare PartnersRA Capital
BiotechBurlingame, US
Mark Rolfe(Executive Officer)Laura Shawver(Executive Officer, Director)inTimothy Smith(Executive Officer)
BoardAlfred Scheidegger(Director)inPeter Thompson(Director)inCarol Gallagher(Director)in
Co-investorsAstellas Venture Management LLCNew Enterprise Associates (NEA)Nextech InvestOUP (Osage University Partners)5AM VenturesClarus Ventures+1 more
Convergent provides an AI simulation platform for enterprise training and skill development.
AI & Machine LearningEnterprise SoftwareHR TechSaaSLondon, GB
Co-investorsTechstarsAndreessen HorowitzRA Capital
Corvus Pharmaceuticals is a biopharmaceutical company developing immunology-focused medicines that target cellular components of the immune system, with therapeutic focus on immune diseases and cancer.
BiotechHealthtechBurlingame, US
Richard A. Miller(President & CEO, Co-Founder)inLeiv Lea(Executive Officer)in
BoardElisha (Terry) P. Gould(Director)Peter Moldt(Director)Peter Thompson(Co-Founder)inTerry G. Gould(Director)
Co-investorsAvoro Capital AdvisorsForesite CapitalRoche Venture Fund
Lang Lai Technology (朗来科技) is a clinical-stage drug discovery company that runs an end-to-end new-drug R&D process spanning proof of concept, candidate compound screening, preclinical druggability development, and clinical research, pursuing both pipeline development and platform building.
BiotechHealthtechWuhan, CN
Co-investorsVivo CapitalLilly Asia Ventures
Curevo Vaccine is a biotech company developing next-generation non-mRNA vaccines, with a focus on infectious diseases.
BiotechHealthtechBothell, US
George Simeon(CEO)inGregory S. Curhan(CFO)Guy De La Rosa(CMO)in
Co-investorsAdjuvant CapitalHBM Healthcare InvestmentsMedicxiRA CapitalSanofi VenturesJanus Henderson Investors
Cyrus operates a protein engineering platform that combines AI and Rosetta computational design methods with a biochemistry lab performing large-scale deep mutagenesis scanning, protein stabilization, immunogenicity reduction, and affinity/specificity tuning.
AI & Machine LearningBiotechDeep TechSeattle, US
Yifan Song(CSO)inDavid Baker(Co-founder)Javier Castellanos(Executive Officer, Director)inMark(President & EVP, Business Development)
BoardLucas Nivon(CEO)in
Co-investorsAlumni VenturesAnzu PartnersArgonautic VenturesiSelect FundSPRINGROCK VENTURESStrawberry Creek Ventures+4 more
Cyrus provides a mobile app for personal cybersecurity and financial protection, offering account monitoring, dark web scanning, credit monitoring across three bureaus, VPN services, and fraud support for consumers.
ConsumerCybersecurityDigital Health
Co-investorsGaingelsRainfall VenturesResolute VenturesSPRINGROCK VENTURESThe Fintech FundTrinity Ventures
大米和小米 (DMHXM) operates a network of over 80 directly-run centers across more than 30 Chinese cities providing in-person early intervention and rehabilitation therapy for children with autism and developmental disorders, staffed by BCBA/BCaBA-certified therapists and experienced supervisors.
Digital HealthHealthtechWellness & FitnessShenzhen, CN
Co-investorsYuanBio Venture Capital
DELFI Diagnostics develops FirstLook Lung, a blood-based laboratory test for lung cancer screening that identifies genome-wide alterations in individuals eligible for screening.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesBaltimore, US
Victor Velculescu(Founder)inPeter Bach(Executive Officer)Jennifer Buechel(Executive Officer)Douglas Schenkel(Executive Officer)Nicholas Dracopoli(Executive Officer)inSusan Tousi(Chief Executive Officer)in
Co-investorsAV8 VenturesForesite CapitalIllumina VenturesInitiate Venture PartnersMenlo VenturesMerck Global Health Innovation Fund+7 more
Dimension Therapeutics was a Cambridge, Massachusetts biopharmaceutical company developing AAV-based gene therapies for rare liver-associated metabolic diseases like hemophilia, OTC deficiency, and glycogen storage disease.
Cambridge, US
Annalisa Jenkins(Executive Officer, Director)
BoardBenjamin Auspitz(Director)Donald J. Hayden(Director)Allan Fox(Director)
Co-investorsF-Prime CapitalNew Leaf Venture Partners
EC Healthcare provides medical aesthetic and healthcare services, including sales of medical aesthetic products, to consumers.
ConsumerDigital HealthHealthtechWellness & FitnessHong Kong, HK
Eilean Therapeutics is a small molecule oncology drug discovery company developing pan-variant therapies that target resistance mechanisms in hematologic malignancies.
BiotechHealthtech
Iain Dukes(CEO)inJohn Byrd(Interim Chief Medical Officer)Nikolay Savchuk(COO)Amy Burd(CSO)Brian Ledwith(Chief Development Officer)Fraser Pickersgill(Head CMC)
Electra Therapeutics develops antibody therapeutics targeting Signal Regulatory Protein (SIRP) for immunological diseases and cancer treatment.
BiotechHealthtechMedical DevicesSouth San Francisco, US
Adam Rosenthal(Co-founder and former CEO; Director)inQuehuong (Kathy) Dong, Pharm.D.(Executive Officer, Director)Kathy Dong(President, Chief Executive Officer and Director)in
BoardBeth Seidenberg, M.D.(Director)Thomas Geninatti, Ph.D.(Director)Carl Gordon, Ph.D.(Director)
Co-investorsHBM Healthcare InvestmentsHBM PartnersRA CapitalWestlake Village BioPartnersKleiner PerkinsNVIDIA
Epigenic Therapeutics develops gene regulation-based biotherapeutics using its EPIREG platform, which applies AI algorithms to design CRISPR-Cas components that regulate target gene expression without altering the DNA sequence.
AI & Machine LearningBiotechDeep TechHealthtechMedical Devices
Chloe You(Chief Medical Officer)inKelly Shi(Chief Financial Officer)
Co-investorsQiming Venture PartnersTrinity Innovation Bioventure Singapore
Evox Therapeutics develops exosome-based gene editing therapies using its ExoEdit platform, which combines exosome delivery with a proprietary CRISPR-based editor to treat severe neurodegenerative and other genetically-driven diseases.
BiotechDeep Tech
Co-investorsGV (Google Ventures)Oxford Science EnterprisesPanacea VentureCowen Healthcare InvestmentsREDMILE
Evozyne designs and builds engineered protein therapeutics using an AI-native platform, focusing on treatments for immune-mediated diseases.
AI & Machine LearningBiotechDeep TechHealthtechChicago, US
Aris Theologis(Executive Officer, Director)inDarien Parhad(Executive Officer)Patrick J. Morris(Executive Officer, Director)Marc Yoskowitz(CEO)inRama Ranganathan(Founder)Andrew Ferguson(Founder)
Co-investorsParagon Biosciences LLCIn-Q-TelNVIDIAValor Equity PartnersFidelity InvestmentsNVentures
Fore Biotherapeutics is a clinical-stage oncology company developing targeted cancer therapies, including its lead plixorafenib program.
BiotechHealthtechMedical DevicesPhiladelphia, US
Co-investorsHBM Healthcare InvestmentsHBM PartnersLG Technology VenturesNovartis Venture FundPontifax Venture CapitalSR One Capital Management+4 more
Developed biotech research instruments for measuring molecular binding; acquired by Pall Corporation for $159M.
Co-investorsLatterell Venture PartnersThe Vertical GroupMPM BioImpactVersant Ventures
Fusion Pharma develops targeted alpha therapeutics that link alpha-emitting medical isotopes to molecules targeting biomarkers on cancer cell surfaces to selectively kill tumor cells.
BiotechHealthtech
John Valliant(Founder)in
Co-investorsFACIT (Fight Against Cancer Innovation Trust)HealthCapLumira VenturesPivotal Life SciencesSeroba Life SciencesVenture Ontario+6 more
FUS Mobile develops the Neurolyser XR, a non-invasive medical device that uses high intensity focused ultrasound (HIFU) with fluoroscopic guidance to thermally ablate the lumbar medial branch nerve for treating chronic facet-mediated low back pain.
Deep TechDigital HealthHardwareHealthtechMedical Devices
Co-investorsAtlanta Technology Angels
Damora Therapeutics is a biotechnology company developing subcutaneous biologics as targeted, disease-modifying treatments for patients with mutant calreticulin (mutCALR)-driven myeloproliferative neoplasms such as essential thrombocythemia and myelofibrosis.
BiotechMedical Devices
Jennifer Jarrett(Chief Executive Officer & Board Director)inSherwin Sattarzadeh(Chief Operating Officer)inBecker Hewes(Chief Medical Officer)Garrett Winslow(General Counsel)inJim Baker(Chief Corporate Affairs Officer)inBrian Burkavage(Senior Vice President, Finance)in
Co-investorsEIR VenturesHadean VenturesM VenturesSEED Capital DenmarkSeventure PartnersSunstone Capital+3 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
BELLUS HealthClementia PharmaceuticalsCurevo, Inc.FORE US BioIgenica BiotherapeuticsIkena Oncology, Inc.Prevail TherapeuticsRestora MedicalSpringWorks TherapeuticsSymbiomix TherapeuticsADARxAduro BiotechAige010Aragon PharmaceuticalsAttenuaAvalo TherapeuticsAzura OpthalmicsBailiBiokinBionovapharmaBlossomHill TherapeuticsCreditpharmaDlabsciEddingpharmEthrisEurolifehealthcareForSight VISION6 IncFortebiorxFuturxGaush
Browse all 337 investments with full details →
▶137 more tracked companies
GelesisGenewizGennaoGenocuryGood Doctor Cloud HealthHarpoon TherapeuticsHarvestiroHelicore BiopharmaHysyylIambicIkenaoncologyImmune PathInnovate BiopharmaceuticalsInnvolutionInnvolution Healthcare Private LimitedIntelliaInventisbioIswarya FertilityJanux TherapeuticsJinxin Fuxing EldercareJxfxkyKapivaKartostheraKoya MedicalKumquat BiosciencesLaekna TherapeuticsLattice MedTech Private LimitedLaxmi DentalLaxmidentallealLeal TherapeuticsLexeotxLifecellLogicbioLomondtherLoxoLoxo OncologyLupeng PharmaceuticalLycia TherapeuticsMagenta MedicalMarksans PharmaMBXMBX BiosciencesMDxHealthMedpharmMendraMID LabsMinghuipharmaMinvervaXMiradorMirador TherapeuticsMobileodtMondegobioMyriad GeneticsNanotronicsNerre TherapeuticsNeurelisNewmedNorchem PharmaNucleixNucleusradOdyssey TherapeuticsPath AiPathalysPee SafePic TherapeuticsPinnacle MedicinesPionyr ImmunotherapeuticsPMV PharmaPostmatesPractice FusionPrincipia BiopharmaProlynxProlynxincPropellerProVerumProviva TherapeuticsPulnovo MedicalRadiuspharmRampart BioscienceRAPT TherapeuticsRayTheraReCode TherapeuticsReliabiotechRenasant BioRepare TherapeuticsReparerxReViralSeroba Life SciencesSidewinder TherapeuticsSikkaSikkasoftSilverback TherapeuticsSingulexSitalaSiteOne TherapeuticsSneuroSpectronrxStairmedStar TherapeuticsStarling OncologyStratus TherapeuticsSuraksha DiagnosticSynthorxTandemaiTendfoTerremoto BiosciencesThe Oncology InstituteTheseusThird Harmonic BioTigerConnectTopaz TxTP TherapeuticsTriSalus Life SciencesTrisaluslifesciTriveniTrunativTurnstone BiologicsTytoTyto CareUnilifeUpper BiotechUrotronicVelosbioVelseraVerdiva BioVerrica PharmaceuticalsVivacta BioVvardisWindward BioYarrowYarrowbioscienceZaiZentera TherapeuticsZenteratxZion PharmaZyloxtb
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 63
50 IPOs · 13 acquisitions · showing 55Q32 BioNASDAQ: QTTBScribe TherapeuticsNASDAQ: SCTXSionna TherapeuticsNASDAQ: SIONUpstream BioNASDAQ: UPBAadi BioscienceNASDAQ: WHWKAdicet BioNASDAQ: ACETArvinas Holding Co. LLCNASDAQ: ARVNCalcimedicaNASDAQ: CALCCompass TherapeuticsNASDAQ: CMPXImaraNASDAQ: ELVNKeros TherapeuticsNASDAQ: KROSMirna TherapeuticsOTC: SYBXNextCureNASDAQ: NXTCPrelude TherapeuticsNASDAQ: PRLDSI-BONENASDAQ: SIBNSpruce BiosciencesNASDAQ: SPRBSynlogicOTC: SYBXAdaptive BiotechnologiesNASDAQ: ADPTAlumisNASDAQ: ALMSAura BiosciencesNASDAQ: AURAAvita MedicalNASDAQ: RCELBioAge LabsNASDAQ: BIOABiomxNYSE: PHGECaris Life SciencesNASDAQ: CAICrinetics PharmaceuticalsNASDAQ: CRNXCullinan TherapeuticsNASDAQ: CGEMCytomX TherapeuticsNASDAQ: CTMXDamora TherapeuticsNASDAQ: DMRADarioHealthNASDAQ: DRIODisc MedicineNASDAQ: IRONEdgewise TherapeuticsNASDAQ: EWTXEmergent BiosolutionsNYSE: EBSEnliven TherapeuticsNASDAQ: ELVNForte BiosciencesNASDAQ: FBRXInsmedNASDAQ: INSMInspireMDNASDAQ: NSPRIntellia TherapeuticsNASDAQ: NTLAInvivydNASDAQ: IVVDNeuroPaceNASDAQ: NPCEOncology InstituteNASDAQ: TOIOnconova TherapeuticsNASDAQ: TRAWORIC PharmaceuticalsNASDAQ: ORICPassage BioNASDAQ: PASGRelmada TherapeuticsNASDAQ: RLMDShattuck LabsNASDAQ: STTKSonendoOTC: SONXTELA BioNASDAQ: TELATrawspharmaNASDAQ: TRAWVerastemNASDAQ: VSTMVerricaNASDAQ: VRCAAduro Biotechacq. by Chinook TherapeuticsAvedro, Inc.acq. by GlaukosAvitideacq. by RepligenDimension Therapeuticsacq. by Ultragenyx PharmaceuticalForteBioacq. by Pall
Portfolio news
latest coverage across their companies
Invivyd · investors.invivyd.com · Sep 1, 2026
InspireMD · manilatimes.net · Aug 17, 2026
Rhythm Pharmaceuticals · massbio.org · Aug 14, 2026
Spruce Biosciences · stocktitan.net · Aug 12, 2026
Aura Biosciences · stocktitan.net · Aug 12, 2026
Fund performance · per public LP disclosures · 10
as of Sep 2025| Fund | Vintage | Committed | Net IRR | TVPI | DPI |
|---|---|---|---|---|---|
| OrbiMed Private Investments IX, LPLPs: California State Teachers' Retirement System, New Mexico Educational Retirement Board, Kern County Employees' Retirement Association | 2022 | — | 29.3% | 1.16x | 0.21x |
| OrbiMed Royalty & Credit Opportunities IVLPs: California State Teachers' Retirement System, Sacramento County Employees' Retirement System, Kern County Employees' Retirement Association | 2022 | — | 14.1% | 1.28x | 0.25x |
| OrbiMed Private Investments VIII, L.P.LPs: California State Teachers' Retirement System, New Mexico Educational Retirement Board | 2020 | — | 6.9% | 1.19x | 0.30x |
| OrbiMed Royalty & Credit Opportunities III, LPLPs: California State Teachers' Retirement System, Sacramento County Employees' Retirement System | 2019 | — | 15.1% | 1.20x | 0.95x |
| OrbiMed Private Investments VILPs: Oregon Public Employees Retirement System | 2015 | — | 13.0% | 1.64x | 1.18x |
| OrbiMed Private Investments VLPs: Oregon Public Employees Retirement System, California State Teachers' Retirement System | 2013 | — | 38.2% | 2.35x | 2.14x |
| OrbiMed Private Investments IVLPs: Oregon Public Employees Retirement System, California State Teachers' Retirement System, The Regents of the University of California +1 more | 2009 | — | 31.8% | 2.73x | 2.72x |
| Orbimed Private lnvesuncnts IV, L PLPs: The Regents of the University of California | 2009 | — | 36.2% | 2.67x | 0.45x |
| Orbimed Private Investments III, LPLPs: The Regents of the University of California | 2006 | — | 18.1% | 2.34x | 1.48x |
| Orbimed Private lnvesunents Ill, LPLPs: The Regents of the University of California | 2006 | — | 18.4% | 2.32x | — |
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).
IPO stake values · per SEC filings · 16
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Prelude Therapeutics | 28.8% | $60.00 | Jan 2021 | $935.7M |
| Passage Bio | 14.2% | $18.00 | Feb 2020 | $112.7M |
| NextCure | 10.1% | $36.75 | Nov 2019 | $99.6M |
| Invivyd | 4.6% | $17.00 | Aug 2021 | $84.7M |
| Upstream Bio | 9.5% | $17.00 | Oct 2024 | $82.8M |
| ORIC Pharmaceuticals | 8.2% | $23.00 | Nov 2020 | $67.2M |
| Adicet Bio | 15.8% | $15.00 | Jan 2018 | $64.5M |
| NeuroPace | 16.4% | $17.00 | Apr 2021 | $64.2M |
| Calcimedica | 17.9% | $16.00 | Sep 2020 | $57.6M |
| Sionna Therapeutics | 7.4% | $18.00 | Feb 2025 | $56.8M |
| Damora Therapeutics | 13.7% | $15.00 | Oct 2020 | $50.4M |
| Intellia Therapeutics | 6.9% | $18.00 | May 2016 | $43.4M |
| Imara | 9.6% | $16.00 | Mar 2020 | $25.5M |
| Enliven Therapeutics | 9.6% | $16.00 | Mar 2020 | $25.5M |
| Verrica | 5.1% | $15.00 | Jun 2018 | $19.2M |
| Scribe Therapeutics | 2.0% | $15.00 | Jul 2026 | $5.2M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- How many investments has OrbiMed made?
- OrbiMed has 337 tracked investments, 63 of which have exited, including 38 dated in the last 24 months.
- What stage does OrbiMed invest at?
- OrbiMed invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What is OrbiMed's typical check size?
- OrbiMed typically writes checks of $1M – $75M.
- What sectors does OrbiMed focus on?
- OrbiMed focuses on AI & Machine Learning, Biotech, Digital Health, Healthtech, Longevity, Medical Devices.
- Where is OrbiMed located?
- OrbiMed is headquartered in New York, US.
- Does OrbiMed lead rounds?
- Yes, OrbiMed leads investment rounds.
- Who does OrbiMed co-invest with?
- OrbiMed most often shares deals with Foresite Capital, RA Capital, Frazier Life Sciences, among 278 tracked co-investors.
Media · Podcasts & interviews
featuring the teamGeoffrey C. Hsu, CFA, General Partner, OrbiMed Advisors LLC
Biotechnology Innovation Organization · Geoffrey C. Hsu
Co-investors · 87
RA Capital Management is a healthcare and planetary health investment firm that founds, funds, and scales companies using scientific diligence, multi-stage capital, and hands-on operational support.
Foresite Capital is a healthcare-focused investment firm backing companies at the intersection of technology and biotechnology to personalize healthcare and accelerate medical innovation.
Lilly Asia Ventures (LAV) is a biomedical venture capital firm with offices in Hong Kong, Shanghai, and Palo Alto, backing entrepreneurs building companies focused on breakthrough products that treat disease and improve human health.
New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.
Sofinnova is an investment firm focused on the life sciences and biotechnology sector, partnering with companies from inception through drug development, regulatory approval, company building, and IPO.
F-Prime Capital is an early-stage-focused investment firm backing companies across life sciences, technology, healthtech and services, and crypto.
SR One Capital Management is a life sciences venture firm that takes a back-and-build approach to investing in biotech and therapeutics companies, supporting entrepreneurs with human, intellectual, and financial resources.
5AM Ventures is a life science venture capital firm founded in 2002 that funds and builds next-generation life sciences companies, focusing on biopharmaceuticals, drug delivery technologies, and life science instruments.
Samsara BioCapital is a life-sciences investment firm backing companies developing transformative therapeutics for patients.
Atlas Venture is a biotechnology-focused venture firm that creates and builds breakthrough life science companies, backing entrepreneurs to translate scientific research into new medicines.
OUP (Osage University Partners) is a venture firm that invests in science-driven startups commercializing deep technology innovations emerging from university research and breakthrough science.
Pfizer Venture Investments is a strategic venture fund that doesn't require product or technology rights as a condition of investing, giving founders independence while still aiming for future collaboration with Pfizer, and its team blends venture investing with business development and drug discovery expertise to back frontier scientific bets—such as neuroscience, in-vivo cell engineering, dark-genome target discovery, and the blockchain-based longevity accelerator VitaDAO—that many biotech investors avoid. The fund also runs an active China strategy through a locally based venture vehicle and direct investments like OTR Therapeutics, and it has become a channel for strategic deals, with portfolio companies acquired by AbbVie, Ipsen, and Gilead/Kite.
▶75 more co-investors
Aisling CapitalVivo CapitalNextech InvestSanofi VenturesAvoro Capital AdvisorsHBM PartnersvenBio PartnersAndreessen HorowitzVersant VenturesOmega FundsGV (Google Ventures)Canaan PartnersUS Venture PartnersForbionDeerfield Management CompanyNew Leaf Venture PartnersRTW Investments L.P.Khosla VenturesKleiner PerkinsGeneral AtlanticThird Rock VenturesAbingworthPivotal Life SciencesSV Health InvestorsAndera PartnersAdvent Life SciencesSequoia CapitalFounders FundLightspeed Venture PartnersThe Column GroupFrazier Healthcare PartnersVida VenturesWestlake Village BioPartnersJMI EquityBorealis VenturesGeneral CatalystMenlo VenturesTiger Global ManagementTrinity VenturesVenrockPear VCPitangoSofinnova PartnersMPM BioImpactHatteras Venture PartnersYsios Capital6 Dimensions CapitalLongwood FundBessemer Venture PartnersCRV (Charles River Ventures)Polaris PartnersEQT Life SciencesDimension CapitalRiverVest Venture PartnersDCVC (Data Collective)Meritech Capital PartnersDomain AssociatesFlagship Pioneering1955 CapitalDFJSeroba Life SciencesAmplitude Venture CapitalAction Potential Venture Capital Ltd.ACORN BIOVENTURESCincyTechDe Novo VenturesSignet Healthcare PartnersWelsh, Carson, Anderson & StoweZetta Venture PartnersWildcat Venture PartnersM12 (Microsoft's Venture Fund)BDC Venture CapitalTencent HoldingsCofounders Capital+ND Capital
Firms observed investing alongside OrbiMed, from public investor directories. Shared companies are the overlap with OrbiMed's recorded portfolio.
Similar investors
GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.
Foresite Capital is a healthcare-focused investment firm backing companies at the intersection of technology and biotechnology to personalize healthcare and accelerate medical innovation.
aMoon is a healthcare and life sciences-focused investment firm that partners with scientists and entrepreneurs building companies at the convergence of technology and biology to transform healthcare and accelerate cures.
A globally recognized venture capital firm designed to provide access to highly competitive venture deals to individual investors, consistently recognized for top-decile DPI performance and as one of the most active US venture firms.
Alumni Ventures (AV) is a venture capital firm that co-invests alongside lead VCs in startups, backing founders with capital and access to a large investor and operator community.